



**HAL**  
open science

## Virus-Mediated Cell-Cell Fusion

Héloïse Leroy, Mingyu Han, Marie Woottum, Lucie Bracq, Jérôme Bouchet,  
Maorong Xie, Serge Benichou

► **To cite this version:**

Héloïse Leroy, Mingyu Han, Marie Woottum, Lucie Bracq, Jérôme Bouchet, et al.. Virus-Mediated Cell-Cell Fusion. *International Journal of Molecular Sciences*, 2020, 21 (24), pp.9644. 10.3390/ijms21249644 . hal-03411652

**HAL Id: hal-03411652**

**<https://hal.science/hal-03411652>**

Submitted on 22 Nov 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Review

# Virus-Mediated Cell-Cell Fusion

Héloïse Leroy <sup>1,2,3</sup>, Mingyu Han <sup>1,2,3</sup>, Marie Woottum <sup>1,2,3</sup>, Lucie Bracq <sup>4</sup>, Jérôme Bouchet <sup>5</sup>,  
Maorong Xie <sup>6</sup> and Serge Benichou <sup>1,2,3,\*</sup>

<sup>1</sup> Institut Cochin, Inserm U1016, 75014 Paris, France; heloise.leroy@inserm.fr (H.L.); mingyu.han@inserm.fr (M.H.); marie.woottum@inserm.fr (M.W.)

<sup>2</sup> Centre National de la Recherche Scientifique CNRS, UMR8104, 75014 Paris, France

<sup>3</sup> Faculty of Health, University of Paris, 75014 Paris, France

<sup>4</sup> Global Health Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland; lucie.bracq@epfl.ch

<sup>5</sup> Laboratory Orofacial Pathologies, Imaging and Biotherapies UR2496, University of Paris, 92120 Montrouge, France; jerome.bouchet1@parisdescartes.fr

<sup>6</sup> Division of Infection and Immunity, University College London, London WC1E 6BT, UK; maorong.xie@ucl.ac.uk

\* Correspondence: serge.benichou@inserm.fr

Received: 20 November 2020; Accepted: 14 December 2020; Published: 17 December 2020

**Abstract:** Cell-cell fusion between eukaryotic cells is a general process involved in many physiological and pathological conditions, including infections by bacteria, parasites, and viruses. As obligate intracellular pathogens, viruses use intracellular machineries and pathways for efficient replication in their host target cells. Interestingly, certain viruses, and, more especially, enveloped viruses belonging to different viral families and including human pathogens, can mediate cell-cell fusion between infected cells and neighboring non-infected cells. Depending of the cellular environment and tissue organization, this virus-mediated cell-cell fusion leads to the merge of membrane and cytoplasm contents and formation of multinucleated cells, also called syncytia, that can express high amount of viral antigens in tissues and organs of infected hosts. This ability of some viruses to trigger cell-cell fusion between infected cells as virus-donor cells and surrounding non-infected target cells is mainly related to virus-encoded fusion proteins, known as viral fusogens displaying high fusogenic properties, and expressed at the cell surface of the virus-donor cells. Virus-induced cell-cell fusion is then mediated by interactions of these viral fusion proteins with surface molecules or receptors involved in virus entry and expressed on neighboring non-infected cells. Thus, the goal of this review is to give an overview of the different animal virus families, with a more special focus on human pathogens, that can trigger cell-cell fusion.

**Keywords:** virus; cell-cell fusion; syncytia; virus spreading

---

## 1. Introduction

Viruses are acellular organisms in which the genomes consist of RNA or DNA nucleic acid and which obligatory replicate inside host cells. Using cellular machineries, viral components are synthesized and then assemble into particles called virions, which serve to protect the genome for subsequent transfer to other target cells for virus dissemination. In addition, numerous viruses have a lipid bilayer external envelope that surrounds the viral particle. The process generally described for animal virus dissemination between permissive cells is related to release of cell-free viral particles that diffuse from infected cells and subsequently attach and enter new target cells for virus replication. The first step of this process is the recognition of cellular attachment molecules and receptors expressed on the surface of the target cell by virus-encoded proteins found on the surface

of the virus particle. Recognition and binding to cellular receptors is followed by virus entry for replication. However, many viruses, including some viruses that are pathogenic for humans, can also move between cells without diffusing through the extracellular environment by cell-to-cell spreading. Virus cell-to-cell spread may not only facilitate rapid viral dissemination but may also promote immune evasion and contribute to pathogenesis.

Several distinct mechanisms for virus cell-to-cell transfer and spreading have been described, but some viruses can use the fusogenic capacity of some viral proteins, usually involved in virus entry, expressed at the surface of infected cells to trigger cell-cell fusion between infected virus-donor cells and neighboring target cells to form enlarged multinucleated cells, often called syncytia. Three main different classes of viral fusion proteins have been structurally described depending the conformational structure and mechanism use for fusion of the viral bilayer envelope with the cell membranes [1]: class I, with a characteristic  $\alpha$ -helix trimer (as in HIV-1 transmembrane gp41); class II, with a  $\beta$ -sheet-based elongated ectodomain (as in dengue virus glycoprotein); and class III, composed of an  $\alpha$ -helix and  $\beta$ -sheet combined ectodomain (as in rabies virus G glycoprotein). In addition, a fourth class of fusion proteins corresponding to the FAST protein family of some non-enveloped Reoviruses has been also described. Thereby, virus-induced cell-cell fusion and syncytium formation are mainly mediated by specific interactions of certain viral fusion proteins with surface molecules or receptors expressed on neighboring non-infected cells.

Several viral families, including some human pathogens, have evolved the ability to trigger cell-cell fusion to form syncytia between individual infected cells and neighboring uninfected or infected cells. Even if the specific role of these virus-induced syncytia for pathogenesis during the natural course of some viral infections is still discussed, these infected multinucleated cells can show high capacity of viral production and improved capacities of motility or survival, at least when recapitulated in vitro in tissue-culture assays. With the notable exception of some non-enveloped viruses of the Orthoreovirus and Aquareovirus subfamily of *Reoviridae* that use this cell-cell membrane fusion process and syncytium formation for virus dissemination, all other animal viruses able to use cell-cell fusion belong to families of enveloped viruses. For example, HIV-1 and SARS-CoV-2, the two major viral pathogens responsible for the global pandemics of AIDS and COVID-19, respectively, can induce cell-cell fusion and syncytium formation as largely evidenced in tissues, such as brain and lungs, of infected patients. Similarly, the presence of infected multinucleated giant cells in skin lesions has long been recognized as the hallmark of infection by some *Herpesviridae*.

Here, we will review the data of the literature regarding the main families of animal viruses able to trigger cell-cell fusion, and discuss about the mechanisms of this virus-induced cell-cell fusion process, and how this process could contribute in intercellular virus spread, virulence, and virus persistence.

### 1.1. *Herpesviridae*

*Herpesviridae* are a large and diverse family of enveloped double-strand DNA viruses which have a very broad host range and can establish long-life persistent infections. The human *Herpesviridae* family is divided into three subfamilies:  $\alpha$ -herpesviruses, composed of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2, also called HHV-1 and HHV-2, respectively), and varicella-zoster virus (VZV, or HHV-3), are fast-growing cytolytic viruses that establish latent infections in neurons;  $\beta$ -herpesviruses, including human cytomegalovirus (HCMV, or HHV-5) and human herpesviruses 6 and 7 (HHV-6 and HHV-7), are slow-growing viruses that become latent in secretory glands and kidneys; and  $\gamma$ -herpesviruses, composed of Epstein-Barr virus (EBV, or HHV-4) and human herpesvirus 8 (HHV-8, or Kaposi sarcoma-associated herpesvirus) are latent in lymphoid tissues, with a high restricted host range.

The formation of multinucleated giant cells (MGCs) (or syncytia) following Herpesvirus infection in their natural hosts has been well documented for a long time [2–4]. The presence of MGCs in skin lesions has indeed long been recognized as the hallmark of Herpesvirus infection [5] and could be used as diagnostic for Herpes simplex keratitis in eyes [6]. Similarly, MGC formation is also a cytopathologic feature of Herpesvirus infection in the lower respiratory tract [7]. The extent of

Herpesvirus-mediated cell-cell fusion leading to MGC formation is related to the identity of the Herpesvirus but also to the infected tissue: VZV infection results in extensive syncytium formation in skin lesions [8], while HSV-2 induces limited syncytia consisting of only a minor population of infected cells in the skin lesions [9]. However, the significance of Herpesvirus-mediated cell-cell fusion for virus replication and spreading in vivo remains unclear. In in vitro tissue culture, the degree of cell-cell fusion mediated by different clinical isolates and laboratory-adapted strains can significantly vary [10,11]. For example, HSV-1 primary isolates cause limited cell-cell fusion [12], whereas viral variants from laboratory stocks induce extensive syncytial formation in tissue culture [13,14].

Herpesviruses enter host cells by enabling membrane fusion of viral envelopes with host cellular membranes, which either occurs at the plasma membrane or in endosomal compartments. This viral entry process is cell-type dependent and depends on the identity of the Herpesvirus. The viral core membrane fusion machinery required for cell-free virus entry but also for cell-cell fusion induced by herpesviruses consists of the viral glycoprotein gB, a type III viral membrane fusion protein that forms homotrimers, and the heterodimer gH/gL, which are conserved envelope proteins among all Herpesviruses [15,16]. gB is a major determinant of Herpesvirus infectivity both in vitro and in vivo [17,18], while the gH/gL heterodimer can interact with the gB and is required for its fusogenic function [19]. The requirement of the gB homotrimers and gH/gL heterodimer for virus entry into target cells is a highly conserved function among all Herpesviruses [20]. The general process for virus cell-fusion of Herpesviruses first involves activation of the gH/gL heterodimer upon binding to the cellular receptors leading to activation and conformational change of gB [20,21] for insertion of its fusion loops into the host cell membrane, followed by the refolding of gB to drive merge of the viral envelope with the cell membrane [16]. The core fusion machinery is required both for entry of cell-free Herpesviruses into target cells and Herpesvirus-induced cell-cell fusion [15–22]. However, the mechanism of Herpesvirus-induced cell-cell fusion is still poorly understood and is highly cell type-dependent, suggesting that specific cellular cofactors may play important roles in this process. For example, VZV induces extensive syncytial formation of primary keratinocytes but poorly causes cell-cell fusion of primary fibroblasts [8].

In addition, the membrane fusion process sometimes also involved non-conserved membrane glycoproteins specific to each Herpesvirus, which can bind to host cell-specific receptors. For example, HSV-1 and HSV-2 express a non-conserved glycoprotein gD that binds to different host cell receptors depending of the target cell [23]: nectin-1 and nectin-2, cell adhesion molecules expressed on neurons and epithelial cells [24]; the Herpesvirus entry mediator (HVEM), also called Herpesvirus entry mediator A (HveA) or tumor necrosis factor receptor superfamily member 14 (TNFRSF14), expressed on activated lymphocytes [25]; and a non-protein receptor called soluble 3-O-sulfated heparan sulfate [26]. HCMV expresses a glycoprotein gO, as well as 3 small glycoproteins encoded by viral *UL128*, *UL130*, and *UL131* genes, to mediate receptor binding and regulate cellular tropism, but the respective host cell receptors for these additional glycoproteins remain unclear [27,28]. HHV-6A and HHV-6B also express a glycoprotein gO and additional gQ1/gQ2 proteins to engage the CD46 cell surface receptor on human target cells [29,30], but some observations indicated that HHV-6 type B can also use human CD134 as an alternative receptor for viral entry [31]. EBV expresses a soluble gp42 to bind MHC class II receptor HLA-DR1 on B lymphocytes but uses gH/gL heterodimer to directly bind cell surface integrins, such as  $\alpha v\beta 5$ ,  $\alpha v\beta 6$ , or  $\alpha v\beta 8$ , for viral membrane fusion [32,33].

We will now focus on HSV and HCMV for which the process of cell-cell fusion has been best characterized. For HSV (HHV-1 and HHV-2), virus-induced cell-cell fusion and MGC formation for transfer of virus particles from infected cells to uninfected neighboring cells has been initially proposed, in addition to cell-free virus infection, as another mechanism by which viruses spread between host target cells [34,35]. HHV-1 utilizes cell-to-cell spread to move directly from mucosal epithelial cells, the initial site of infection, into nearby sensory neurons, where the virus establishes a latent infection. MGCs (also referred as poly-karyocytes) were first described in skin lesions of HSV-infected patients many years ago, and have even been used for diagnostic purposes of HSV infection in skin biopsies [5]. Similarly, early studies described the formation of MGCs when human epithelial

cells were infected with primary HSV strains isolated from eyes or the oral cavity of infected patients [36]. These poly-karyocytes formed both in skin lesions and in tissue culture, containing no more than ten nuclei, have been referred to as the 'small MGCs' [37]. However, many HSV variants that cause much more extensive cell-cell fusion in tissue culture were readily isolated from laboratory viral stocks [2–13]. These resulting MGCs may contain hundreds or thousands of nuclei, and result from mutations in one or more viral genes [22–38]. For example, truncations or single-point mutations in the cytoplasmic tail of the gB glycoprotein can cause extensive syncytia formation in tissue culture [39–41]. Cell-cell fusion by syncytial variants requires the activity of the specific glycoprotein gD in addition to the core fusion machinery including gB and the heterodimer gH/gL. The gB and gH/L core fusion machinery and gD are necessary and sufficient to mediate cell-cell fusion [42], but other glycoproteins gM, gE, and gI, and the non-glycosylated membrane protein UL45 can regulate syncytium formation [43]. Cell-cell fusion induced by HSV is also negatively modulated by the glycoprotein K (gK) which regulates the core fusion machinery when co-expressed with gB, gH/gL, and gD [44]. Similarly, the glycoprotein gM downregulates surface expression of both gD and gH/gL heterodimer, inhibiting HSV-1-induced cell-cell fusion [45,46]. gK and UL20 protein form a functional protein complex that physically interacts with gB, thereby modulating the fusogenic properties gB [47]. Finally, the tegument proteins UL11, UL16, and UL21 can form a complex tightly associated with gE on its cytoplasmic tail, to modulate its function for cell-cell fusion [48]. Along with the core fusion machinery, the glycoproteins gE/gI heterodimer is also involved in HSV-induced cell-cell fusion and required for MGC formation [43–49].

Whereas the gD receptors (HVEM, and nectin-1 or nectin-2) are required for HSV mediated cell-cell fusion [50,51], heparan sulfate appears less important for cell-cell fusion than for viral entry [51,52]. It remains elusive how interaction of gD with its entry receptors leads to cell-cell fusion. One hypothesis is that the binding of gD with entry receptors induces conformational changes of gD, enabling its interaction with the core fusion machinery and activation of its fusogenic activity. Other cellular receptors for gB and/or gH/gL may also exist, and the binding of these glycoproteins to these additional receptors could also trigger fusion activity, and bypass the requirement for gD. The paired immunoglobulin-like type 2 receptor (PILR) has been identified as an entry coreceptor that associates with gB, and interactions between PILR and gB are involved in membrane cell-cell fusion events during HSV-1 infection [53]. Interestingly, the cellular protein tyrosine phosphatase 1B (PTP1B) has been recently reported to be specifically required for the cell-cell fusion by HSV-1 and not for cell-free virus infection [54].

Human cytomegalovirus (HCMV) infects a broad range of cell types, such as epithelial cells, endothelial cells, fibroblasts, leukocytes, monocytes, and macrophages [55]. As usual, the ability of HCMV to enter into these different cell types requires the coordinated interactions of viral glycoproteins with multiple host receptors [56]. It has been proposed that HCMV can use different forms of gH/gL heterodimer, including a trimeric complex with the gO glycoprotein and a pentameric complex with UL128 to UL131 proteins, to engage distinct receptors, and this engagement then triggers gB-mediated membrane fusion [57]. In vivo, HCMV spreading is largely cell-associated, and clinical isolates have been shown to induce enlarged flower-shaped syncytial foci in vitro [10,58]. In contrast, laboratory-adapted viral strains spread via diffusion of cell-free virus particles and fail to recapitulate the phenotypic characteristics of virus clinical isolates due to rapid acquisition of genetic mutations [59,60]. The ability of wild-type HCMV to spread via cell-to-cell route through cell-cell fusion can be attributed to the high level expression of the pentameric complex gH/gL/UL128-131, and this cell-to-cell spreading process is resistant to neutralizing antibodies and can overcome specific host restriction factors [60]. Similar to HSVs, HCMV gB and gH/gL are sufficient to mediate cell-cell fusion, and this process is most efficient at neutral pH [61]. Overexpression of gB promotes cell-cell fusion [62,63], whereas gB lacking the cytoplasmic domain fails [64]. In contrast, a single amino acid mutation within gB can promote cell-cell fusion and syncytium formation [65]. Recently, it has been reported that gB-mediated cell fusion and syncytia formation can be potently inhibited by neutralizing monoclonal antibodies (mAbs) specifically targeting the antigenic domain 5 (AD-5) in the ectodomain of gB, which has been shown to possess the predicted fusion loops [66]. In addition,

the glycoprotein gO has been involved in HCMV-induced cell-cell fusion, and anti-gO antibodies can also block syncytium formation [67].

### 1.2. Paramyxoviridae

The *Paramyxoviridae* family contains several human viruses capable of inducing cell-cell fusion, including Sendai, Nipah, and Hendra viruses, as well as the Measles virus (MV) and the human respiratory syncytial virus (HRSV) [68–71]. Paramyxoviruses are spherical, enveloped, viruses with a linear negative-strand RNA genome encoding the nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the fusion protein (F), the large protein (L), and the binding transmembrane glycoprotein (G), which may have a hemagglutinin activity (also named H), associated or not with a neuraminidase activity (called HN). Here, we will focus on Measles virus and respiratory syncytial virus, which are the viruses of this family that have been the most studied for inducing cell-cell fusion and syncytia formation, in vitro, but especially in vivo, in infected patients.

Measles is a highly contagious disease that affects children and young adults, usually causing skin rashes, but severe complications can progress to fatal encephalitis. Measles virus (MV) is an enveloped virus of the Morbillivirus genus that first infects epithelial cells but also dendritic cells and alveolar macrophages of the respiratory tract before spreading by cis-infection to lymphocytes in lymph nodes and finally neurons [72–75]. Virus replication begins with the attachment of the viral envelope protein Hemagglutinin (H) to different receptors (CD46, Signaling Lymphocyte-Activation Molecule (SLAM), also named SLAMF1 or CD150, and Nectin-4) [76]. The wild-type strain of MV preferentially recognizes SLAM which is expressed on both B and T cells, while attenuated vaccine MV strains uses the CD46 receptor widely expressed on all cells [77]. Finally, nectin-4, a cellular adhesion protein of epithelial cell junctions, acts as a co-receptor for virus entry and can be used by both wild type and attenuated vaccine viruses [78]. The virus entry is mediated by both hemagglutinin and the fusion F protein. Hemagglutinin is organized on tetramers at the surface of virions, and is composed of a hydrophobic fusion peptide, two heptad repeat regions A and B (HRA/HRB, respectively) and a transmembrane domain [79]. After binding to the receptor, hemagglutinin induces a coordinated series of conformational changes of the different domains of the F protein, and the final F conformation triggers insertion of the fusion peptide in the host cell membrane, leading to the fusion between virions and the target cell [80], by a pH-independent process at the plasma membrane [79].

MV, but also other Morbilliviruses able to infect dogs, cats, cattle, seals, and cetaceans, are also characterized by their capacity to induce cell-cell fusion, both in vitro and in vivo. The formation of multinucleated cells is one of the major landmark in the development of measles, and has been observed in lymph nodes, respiratory tract and thymus after MV infection [81–83]. In 1973, White and Boy already observed syncytia of infected human thymocytes in lymphoid tissues of infected patients [83]. Similarly, the formation of multinucleated giant cells following MV infection of lymphocytes was initially observed in vivo, in African infected children [84]. Multinucleated giant cells were also initially detected within epidermal cells of Measles skin lesions by electron microscopy [85]. The in vivo MV-infected giant cells are able to produce infectious viral particles and can contribute to viral dissemination in patients [86]. In vitro, MV-induced syncytia have been mainly studied in epithelial cells, but formation of syncytia was also observed in vitro between infected human dendritic cells. Cell-cell fusion was only observed when DCs were activated by lymphocytes through CD40 engagement [87]. More recently, a new study demonstrated that the MV-induced cell-cell fusion leads to an increase of the IFN-I response in infected human epithelial cells and mature dendritic cells, via the nuclear translocation of IRF-3 [70]. In most cell-culture assays used to study MV-induced cell-cell fusion, this process is governed by interaction of viral F and H proteins with the cellular receptors CD46 and SLAM [88]. However, infected epithelial cells, which do not express the SLAM receptor, can form syncytia [89], indicating that the mechanisms by which cell-cell fusion is triggered in MV-infected cells still need better characterization. Interestingly, Kelly et al. [90] have shown in vitro that the formation of syncytia between infected HEK293T cells, a human embryonic

kidney cell-line, expressing the cellular receptor SLAM, was drastically reduced when the lipid raft-associated Tetherin/BST2 protein was overexpressed. Tetherin/BST2 is a cellular restriction factor that restricts replication of numerous viruses, including HIV-1, by clustering viral particles at the cell surface and inhibiting virion release [91]. By using truncation mutants, they showed that the modification of the C-terminal glycosyl-phosphatidylinositol (GPI) anchor of BST2 was sufficient for significant decrease of cell-cell fusion and syncytium formation through targeting of the H protein [90].

Human respiratory syncytial virus (HRSV) is one of the most prevalent viral pathogen responsible for infant lower respiratory diseases, commonly bronchiolitis, but complications can lead to severe pneumonia [92]. HRSV primarily infects superficial airways and type I alveolar epithelial cells [93]. In vivo, infection of epithelial cells leads to the formation of large syncytia, hallmark of the cytopathic effect of HRSV [94]. Unlike other *Paramyxoviridae* as MV, HRSV genome codes for three envelope proteins: the Fusion protein (F), the attachment glycoprotein (G), and the small hydrophobic protein (SH), all involved in virus entry into host target cells [95]. The G protein is a highly glycosylated membrane protein that binds directly to heparin sulfate proteoglycans (Glycosaminoglycans GAGs), as well as to the CX3C-chemokine Receptor 1 (CX3CR1) on the apical surface of polarized epithelial cells [96]. The F protein also facilitates the attachment step by interacting directly with cellular heparan sulfate [97]. Following attachment, a fusion process is realized by the viral F fusion protein, allowing entry of the viral genome into host cells. However, two distinct mechanisms are still debated to explain virus entry. Krzyzaniak et al. [98] reported that in vitro infection of human epithelial HeLa cells was related to an actin-dependent internalization of viruses, which penetrate through Rab5-positive endocytosis vesicles, suggesting a macropinocytosis mechanism for virus entry. The viral F protein is then cleaved by the protease Furin, leading to its fusion with endosomal membranes for release of the viral genome into the cytoplasm [98]. The second proposed mechanism is a fusion process occurring directly at the plasma membrane [99]. In this process, the virus attaches itself on cholesterol microdomains of lipid rafts at the surface of human bronchial epithelial cells. This leads to local cytoskeletal rearrangements through the activation of the Pak1 kinase, resulting in the fusion between the virus and the membrane [99]. These reports indicate that the fusion protein F plays a central role in HRSV-mediated syncytium formation, and it was recently suggested that accumulation of the F protein on cell surface of infected cells helped the binding to the plasma membrane of neighboring uninfected cells. The rapprochement of the two membranes would be followed by the creation of a membrane fusion pore, thanks to the fusogenic activity of the F protein, which allows the formation of multinucleated fused cells for efficient spreading of HRSV [100]. In addition to the viral glycoproteins, cellular factors may be considered in the formation of syncytia mediated by HRSV. Interestingly, Gower et al. [101] demonstrated that the small GTPase RhoA was essential for HRSV-induced cell-cell fusion through modulation of the formation of microvilli at the cell surface [102,103].

### 1.3. *Coronaviridae*

*Coronaviridae* are a family of viruses first characterized in humans in late 1960s which has recently become an increasingly severe threat to global public health, exemplified by the previous outbreaks of Severe Acute Respiratory Syndrome CoV (SARS-CoV) in 2001 and Middle East Respiratory Syndrome CoV (MERS-CoV) in 2012, but especially by the current COVID-19 pandemic induced by SARS-CoV-2 which is responsible for hundreds of thousands of people deaths worldwide [104]. CoVs are enveloped viruses with a positive single-strand RNA genome of around 30 kb in length that encodes for four main viral proteins, the spike protein (S) involved in viral entry, the membrane protein (M), the envelope protein (E) required for virus assembly and release, and the nucleocapsid proteins (N) [105]. The CoV family consists of four sub-families ( $\alpha$ -,  $\beta$ -,  $\gamma$ -, and  $\delta$ -CoVs), among which  $\alpha$ -CoVs and  $\beta$ -CoVs mainly tend to infect mammals, while  $\gamma$ -CoVs and  $\delta$ -CoVs prefer to infect birds and fishes, but some can also infect mammals [106].  $\alpha$ -CoVs include two of the seven human CoVs known to infect humans, such as HCoV-229E and HCoV-NL63, mainly responsible of upper respiratory diseases with symptoms of the common cold but also the porcine epidemic

diarrhea virus (PEDV), while  $\beta$ -CoVs include SARS-CoV, MERS-CoV, and SARS-CoV-2, sharing between 80% and 50% genetic similarity and responsible for the development of severe respiratory diseases, as well as two other human CoV (HCoV-OC43 and HCoV-HKU1) also mainly responsible of common cold that can also advance to severe pneumonia and bronchiolitis, in addition to the mouse hepatitis virus (MHV) [107,108]. Finally,  $\gamma$ - and  $\delta$ -CoVs are mainly involved in fish and bird infections, and they include the avian infectious bronchitis virus (IBV) which can be responsible for severe global economic losses in the poultry industry, but some can also infect mammals, such as the porcine *delta*-CoV (PDCoV) that causes serious vomiting and diarrhea in suckling piglets [106,109–112].

The S spike viral protein plays the critical role for virus entry into target cells, and is the primary determinant of the host tropism and pathogenesis of CoVs. It is a type I highly glycosylated transmembrane protein, which inspired the name “coronavirus” due to its crown-like (corona) shape. The ectodomain of all CoV S proteins share the same organization in two domains: an N-terminal domain named S1 that is responsible for receptor binding at the surface of the target cells, and a C-terminal S2 domain responsible for fusion between the viral envelope and the host-cell membranes that can take place at the plasma membrane or in acidic endosomal compartments after internalization [113,114]. Although the S protein conformational changes can be mainly primed by receptor binding, they can also need additional triggers, such as proteolytic activation or pH acidification, in endosomal compartments [115]. The virus-cell fusion process begins with cleavage of the S protein by cellular proteases that yields the receptor binding domain of S1 and the fusion domain of S2, which is sometimes subsequently again cleaved to generate and expose the fusion peptide directly involved in fusion of the viral and cellular membranes [116–118]. CoVs can recognize different cell surface molecules as their host cell receptors, including proteins, sugars, and heparan sulfate depending of viral sub-families and the receptor binding domains (RBD) of the S spike [104]. Remarkably, CoVs usually can adapt and change receptors for virus cellular entry in the new host either by genetic mutation or recombination to infect a new host species [119]. In addition, CoVs are even capable of recombination when two viruses are infecting the same cell at the same time [119].

The ability of many CoVs, including animal viruses, to mediate cell-cell fusion to form MGCs (or syncytia) has long been well documented, both *in vitro* and *in vivo*, but we will focus here on the three human MERS-CoV, SARS-CoV, and especially SARS-CoV-2 which are responsible for the development of severe and acute respiratory diseases and currently constitute the main threat to public health linked to CoV infections. The presence of infected large syncytia has been definitively observed *in vivo* in lung tissues of infected patients, as evidenced in the large majority of post-mortem lung samples of individuals who died of severe respiratory diseases induced by these three human CoVs. As expected, this cell-cell fusion process and MGC formation can be recapitulated *in vitro* in cell-culture systems [120,121] and is a direct consequence of the high fusogenic activity of the viral Spike protein [122–125].

As mentioned, recent reports show that infected syncytia are frequently observed in lung tissues of SARS-CoV-2-infected patients with acute respiratory syndrome, and immunohistochemistry analyses have identified that these MGCs mainly originate from cell-cell fusion of alveolar epithelial cells. In addition, these SARS-CoV-2-mediated syncytia could also derive from cell-cell fusion of infected alveolar macrophages, target cells that certainly play a crucial role for the systemic hyperinflammation known as “cytokine storm” (or macrophage activation syndrome) observed in patients with critical disease manifestations [123–132]. Some authors even suggest that abnormal cellular syncytia are hallmarks of COVID-19 lung pathology, and it is obvious that some of these giant cells correspond to syncytial histiocytic cells as confirmed by positive CD68 expression, a specific marker of myeloid cells, including monocytes and macrophages [127]. However, the efficiency of cell-cell fusion mainly depends, at least *in vitro*, on viral isolates and host cell-types. For example, SARS-CoV-2 causes extensive MGCs formation in Vero cells, a simian kidney epithelial cell-line largely used to isolate CoVs *in vitro*, whereas relatively few cell-cell fusion events are triggered by SARS-CoV in the same cell-type [133].



Entry into target cells of MERS-CoV relies on binding of the S protein with the surface receptor dipeptidyl peptidase 4 (DPP4) expressed on lung epithelial cells and is then primed by cellular proteases (TMPRSS2 and members of the cathepsin family) which function as activators of the S protein [134,135]. Similarly, in vitro studies show that interaction between the S protein expressed on virus-donor cells and the DPP4 cell surface receptor, as well as priming and activation of the S protein by the cellular TMPRSS2 enzyme, are directly involved in the cell-cell fusion process and MGC formation mediated by MERS-CoV. This cell-cell fusion process can be blocked in vitro by antibodies targeting DPP4 and by the camostat mesylate, a specific inhibitor of the cellular TMPRSS2 protease [133–138]. In addition, the S protein of MERS-CoV seems more efficient than the SARS-CoV S protein for triggering cell-cell fusion of infected cells [136]. Interestingly, cell-cell fusion of MERS-CoV-infected epithelial cells is totally blocked by treatment with the camostat inhibitor, whereas virus entry and infection by cell-free virus particles are only partially inhibited [138], suggesting that the enzymatic activity of TMPRSS2 plays a critical role in MERS-CoV-mediated cell-cell fusion but has a lower impact on cell-free virus infection.

SARS-CoV and SARS-CoV-2 both utilize ACE2 (Angiotensin converting enzyme 2) as host receptor to enter into lung type II epithelial target cells (also called pneumocytes) [115–117,125,126,132,139–141]. Like for MERS-CoV, priming and activation of the S protein involve serine proteases, such as TMPRSS2, for exposure of the S2 domain fusion peptide required for fusion of viral and cellular membranes, as well as for triggering cell-cell fusion between neighboring target cells [121,142–148]. In addition, the S protein of SARS-CoV-2 and MERS-CoV contains, unlike the SARS-CoV S protein, an additional multibasic cleavage site used by the cellular serine protease furin before subsequent activation by TMPRSS2, thus promoting cell-cell fusion and virus cell-to-cell spreading in lung cells [148]. Interestingly, it has been reported that the receptor binding domain of the SARS-CoV-2 S1 subunit binds to ACE2 with a significant higher affinity than the SARS-CoV receptor binding domain [146,147], which may facilitate cell-free virus entry of SARS-CoV-2 into target cells, but also a higher ability to trigger cell-cell fusion of infected cells compared to SARS-CoV. The higher fusogenic activity of the SARS-CoV-2 S2 subunit, compared to that of SARS-CoV, also contributes to this higher ability to mediate cell-cell fusion [149]. Similarly, the S protein of MERS-CoV seems also more efficient than the SARS-CoV S protein for triggering cell-cell fusion of infected cells [136]. Some recent in vitro studies, performed on transfected cell-lines, confirm that infected virus-donor cells expressing the SARS-CoV-2 S spike protein can fuse with adjacent non-infected cells expressing ACE2 and TMPRSS2, leading to the formation of giant syncytia [120,121,148–150]. This syncytium formation process is thus totally inhibited by blocking antibodies targeting the ACE2 receptor, as well as by the camostat mesylate, the specific inhibitor of the TMPRSS2 protease [120,121]. Interestingly, a recent report indicates that some cellular factors such as interferon-induced transmembrane proteins (IFITMs 1, 2, and 3), a family of restriction factors that block entry of many viruses, including HIV-1, negatively modulate syncytium formation through inhibition of the cell-cell fusion process mediated by the S spike protein [120]. However, other currently submitted studies report controversial results showing rather a positive influence of endogenous IFITMs proteins to promote cell-free SARS-CoV-2 infection, as well as syncytia formation in a human lung epithelial cell-line [151]. It is therefore critical to reproduce these observations and perform further investigations using more relevant target cells of SARS-CoV-2, including lung epithelial cells or primary myeloid cells, such as macrophages, to decipher, at the cellular and molecular levels, the mechanisms, as well as the viral and cellular factors, that govern, and may control and modulate, syncytium formation mediated by these three human CoVs.

#### 1.4. *Retroviridae*

*Retroviridae* are a family of enveloped viruses whose genome is formed of two linear copies of single-stranded positive RNA of about 7–11 kb that needs to be reverse-transcribed into a proviral DNA that will be subsequently integrated into the host cell genome [152]. All retroviruses contain at least three major genes encoding the main virion structural components synthesized as polyprotein precursors, Gag, Pol and Env. After proteolytic maturation, these three precursors will give rise,

respectively, (i) to the capsid, matrix and nucleocapsid proteins; (ii) the viral reverse-transcriptase, protease and integrase enzymes involved in essential steps of the viral life cycle; and (iii) the viral envelope glycoproteins involved in virus entry in their host target cells. In addition to virus structural proteins and enzymes, some retroviruses also code for small proteins with regulatory functions.

Retroviral infections can cause a wide spectrum of diseases in their respective hosts ranging from malignancies to immune deficiencies and neurologic disorders. A few human retroviruses have been identified, but only the human immunodeficiency viruses (HIVs) and the human T-lymphotropic viruses (HTLVs), responsible for development of severe immunodeficiency, malignant or neurological diseases, are thus of clinical importance and will be discussed here. As evidenced *in vitro*, these two human retroviruses can induce cell-cell fusion between infected virus-donor cells and uninfected neighboring target cells, leading to the formation of MGCs or syncytia. However, the presence of infected MGCs have been observed *in vivo* only in tissues of HIV-1-infected patients, whereas such observations are still missing regarding HTLV-1 infection.

To date, four types of HTLVs, as well as four types of related simian T-lymphotropic viruses have been identified, but HTLV-1 has been the most studied and is responsible for the development of adult T-cell leukemia/lymphoma and a demyelinating disease called HTLV-associated myelopathy also known as tropical spastic paraparesis [153–156]. HTLV-1 is present in clusters of high endemicity, such as in Japan, equatorial Africa, the Caribbean, and South America [157,158]. Although HTLV-1 primarily infects CD4+ T lymphocytes, other cell types have been found to contain proviral HTLV-1 DNA *in vivo*, including CD8+ T lymphocytes, B lymphocytes, as well as myeloid cells, such as monocytes, macrophages, and dendritic cells. As other retroviruses, the envelope glycoproteins of HTLV-1 involved in virus entry in the target cells is derived from an envelope precursor that is cleaved by cellular proteases yielding the surface subunit (gp46) non-covalently-associated with the transmembrane subunit (gp21). The first step of viral infection relies on successive binding of the surface gp46 to heparan sulfate proteoglycans (HSPGs) [159], neuropilin-1 (NRP-1) [160], and the glucose transporter type 1 (GLUT-1) [161], expressed on target cells. Then, the transmembrane gp21 mediates fusion of the viral envelope with the membrane of the target cell [157,158]. However, HTLV-1 particles are usually not detected in blood of infected patients, and cell-free virions produced *in vitro* are very poor or even not infectious, indicating that HTLV-1 does not spread between its target cells by a cell-free mechanism but primarily uses cell-to-cell processes for virus dissemination. While the most recent studies regarding HTLV-1 cell-to-cell transfer focused on the formation of the so-called “virological synapse” for intercellular virus dissemination [158], it was suggested by previous reports that cell-cell fusion between infected virus-donor cells and target cells leading to syncytium formation could be the main mechanism for HTLV-1 intercellular dissemination [162]. *In vitro*, it is evident that infected cells expressing the viral envelope glycoproteins at the cell surface can fuse with neighboring uninfected cells expressing the different receptors involved in virus entry, leading to syncytium formation that will subsequently die by apoptosis [162–169]. Through their role in establishment and maintenance of tight intercellular junctions, adhesions molecules, such ICAM proteins, expressed at the cell of infected cells also help to trigger cell-cell fusion and syncytium formation by interacting with integrins expressed on target cells [162,165–168]. By contrast, the tetraspanin CD82, a cellular membrane protein that facilitates cellular adhesion, could rather inhibit HTLV-1-mediated syncytium formation through interaction with the viral envelope [170]. Interestingly, it has been also reported that HTLV-1 virions accumulate at the plasma membrane of infected cells in a biofilm-like extracellular viral platform that resembles a bacterial biofilm [171]. This viral biofilm can be rapidly transmitted from infected to neighboring uninfected target cells but could also facilitate cell-cell fusion and syncytium formation. However, to our knowledge, all these results have been described *in vitro*, and there is to date no evidence for the presence of infected syncytia in HTLV-1-infected patients. Therefore, these *in vitro* observations absolutely need to be corroborated with *in vivo* studies that could be performed in relevant animal models, such as STLV-infected monkeys, in order to demonstrate the presence of HTLV-1-induced syncytia during the natural course of infection, as it was observed in HIV-1-infected patients and simian immunodeficiency virus(SIV)-infected macaques.

**Human immunodeficiency viruses**, the etiological agents of AIDS, are classified into two main types: HIV-1 and HIV-2 [152]. While HIV-1 is largely prevalent worldwide, HIV-2 is more closely related to the simian immunodeficiency viruses, but is less pathogenic in humans, and is mostly confined to West Africa. Here, we are referring only to the literature regarding HIV-1 because the huge majority of the data available regarding HIV-mediated formation of infected MGCs are related to HIV-1, even if the presence of infected MGCs have been definitively demonstrated *in vivo* in tissues of SIV-infected monkeys.

HIV-1 targets cells of the immune system expressing the CD4 receptor and one of the chemokine co-receptor, CXCR4 and/or CCR5, for virus entry [172]. Through expression of these receptors and coreceptors, CD4<sup>+</sup> T lymphocytes and cells of the myeloid lineage, including macrophages, dendritic cells, as well as bone osteoclasts, are the main target cells of HIV-1 recognized by the viral envelope, initially produced as a precursor (gp160), and then proteolytically cleaved into two subunits: the surface (gp120) and transmembrane (gp41) subunits that remain non-covalently associated and oligomerize as trimers on the surface of virus particles. The surface gp120 initially binds to CD4 and then to the chemokine receptor on the surface of susceptible cells, leading to subsequent conformational changes of the transmembrane gp41 that finally mediates fusion of the viral membrane with the target cell membrane. The viral envelope also determines the cellular tropism of the viral strains that can be classified in 3 types: CXCR4-using T cell-tropic, CCR5-using T cell-tropic (also called non-macrophage-tropic), and macrophage-tropic strains using either CCR5, CXCR4, or both [173]. In addition to this cell-free infection process, it is now well established, at least for infection of CD4<sup>+</sup> T cells, that HIV-1 can be transmitted and spread through direct cell-to-cell transfer, and this route of infection may be the predominant mode of propagation in infected patients [174]. HIV-1 can take advantage of the specific particularities and functions of its immune cell targets, and subvert intercellular communications to allow infection through a multiplicity of intercellular structures and membrane protrusions, like tunneling nanotubes, filopodia, or lamellipodia-like structures. Other features of immune cells, like the immunological synapse or the phagocytosis properties, can be also hijacked by HIV-1 and used to infect CD4<sup>+</sup> T cells or myeloid target cells. Finally, HIV-1 can use the fusogenic capacity of its envelope glycoproteins to provoke fusion between infected donor cells and neighboring target cells to form infected syncytia (or MGCs) with high capacity of viral production and improved capacities of motility or survival. All these modes of cell-to-cell transfer are now considered as viral mechanisms to escape immune system and antiretroviral therapies and could be involved in the establishment of persistent virus reservoirs in different host tissues [174].

Cell-cell fusion between HIV-1-infected CD4<sup>+</sup> T cells and uninfected CD4<sup>+</sup> T cells has been initially proposed to be another mechanism for HIV-1 infection and dissemination between T cells [175–179]. This cell-cell fusion is mainly mediated through interaction between envelope glycoproteins expressed at the cell surface of infected cells and CD4 and co-receptors expressed on target cells [175–177,179,180], even if adhesion/integrin molecules expressed on virus-donor cells, as well on target cells, facilitate and maintain intercellular contacts for efficient cell-cell fusion. Several groups thus proposed that the cytopathic effect related to the formation of T-cell syncytia could be a mechanism for the CD4<sup>+</sup> T cells loss observed in HIV-1-infected patients [175,176,181]. However, formation of T-cell syncytia has been a controversial subject since other studies did not observe formation of T-cell syncytia using HIV-1-infected primary CD4<sup>+</sup> T cells [182–184], and it has been suggested that these giant syncytia could be *in vitro* artifacts only observed with immortalized cell-lines and restricted to CXCR4-viruses [185]. However, small T-cell syncytia, containing no more than five nuclei, have been then observed *in vivo* in lymph nodes from HIV-1-infected patients [186]. In addition, some more recent studies using HIV-1-infected “humanized mouse” experimental models reported the presence of motile infected syncytia in lymph nodes of infected animals but smaller than those observed *in vitro* [187]. These motile small T-cell syncytia can establish tethering interactions with uninfected T cells that may facilitate virus cell-to-cell transmission and spreading to neighboring target cells in lymphoid tissues [187,188].

While the process of T-cell syncytia formation has been largely documented *in vitro* and discussed for its *in vivo* relevance, some recent reports indicate that these processes of cell-cell fusion

for HIV-1 infection and dissemination are not restricted to T cells since infected multinucleated macrophages, as well as multinucleated DCs, can be found *in vivo* in tissues of HIV-1-infected patients [189,190]. Myeloid cells, such as macrophages and DCs, are indeed poorly infected by cell-free viruses because of the high expression of host cell restriction factors, such as sterile alpha motif and HD-domain-containing protein 1 (SAMHD1), an enzyme that cleaves deoxynucleoside triphosphates (dNTPs) and depletes the pool of intracellular nucleotides necessary for efficient HIV-1 replication in these non-cycling myeloid cells. Therefore, virus cell-to-cell transfer through cell-cell fusion of myeloid cells may likely represent a dominant mode of virus dissemination *in vivo* and may allow for productive infection of these cell types [191,192]. Macrophages have been proposed to participate in virus dissemination and establishment of persistent virus reservoirs in numerous host tissues, including lymph nodes, spleen, lungs, genital and digestive tracts, and the central nervous system (CNS) [193–197]. Virus access to the CNS is indeed mainly related to the migration of infected perivascular monocytes/macrophages through the blood brain barrier and can result in a massive infiltration of infected macrophages often detected as infected MGCs [196,198–205]. Similarly, the presence of HIV-1-infected syncytia derived from DCs and expressing specific markers of DCs and T cells was found at the surface of the nasopharyngeal tonsils, adenoids and parotid glands of HIV-1-infected patients [206–208]. While several groups showed the presence of infected multinucleated macrophages or DCs in tissues, and, more specifically, in the brain of HIV-1-infected patients and monkeys experimentally infected with SIVs, the cellular and molecular mechanisms related to this MGC formation remained poorly investigated [175–209]. Interestingly, we have recently revealed that HIV-1 uses a specific and common two-step cell-cell fusion mechanism for virus transfer and dissemination from infected CD4<sup>+</sup> T lymphocytes to myeloid target cells, including macrophages, immature DCs, and osteoclasts [191,192,210]. In the first step, infected T cells establish contacts with macrophages, OCs or DCs, resulting in the fusion with these myeloid cell targets for virus transfer. Then, the newly formed Gag<sup>+</sup> fused cells acquire the ability to fuse with neighboring uninfected macrophages, DCs or OCs, leading to the formation of infected MGCs that can survive for a long time, at least *in vitro*, and produce high level of fully infectious virus particles. These two sequential cell-cell fusion processes are dependent on interactions of the viral envelope expressed on virus-donor T cells with the CD4 and chemokine co-receptors expressed on myeloid target cells, since they are inhibited by anti-CD4 antibodies, as well as by drugs, such as T20, a specific fusion inhibitor targeting the transmembrane gp41 subunit, and also by co-receptor antagonists. In addition, the viral auxiliary Nef protein is also involved in promoting cell-cell fusion of HIV-1-infected macrophages, and thus participates in the formation of HIV-1-induced MGCs. Importantly, despite their large size, these infected MGCs migrate faster than their infected mononucleated counterparts, and may facilitate virus dissemination in tissues [211]. These recent studies indicate that this two-step cell-cell fusion process leading to the formation of highly virus-productive MGCs allows to bypass the restriction imposed by some host cell restriction factors, such as SAMHD1 [192], and may represent, compared to cell-free virus infection, an original and largely more efficient mode of virus transmission for viral spreading in myeloid cells and may be a major determinant for virus dissemination *in vivo*. These infected MGCs could indeed survive for a long time in host tissues to produce infectious virus particles as shown *in vivo* in lymphoid organs and especially in the CNS of HIV-1-infected patients and SIV-infected monkeys [198–204,208–213]. Similarly, the first step related to the initial cell-cell fusion of infected CD4 T cells with myeloid cell targets agrees with results showing that myeloid cells from lymphoid tissues of SIV-infected macaques contain T-cell markers and viral RNA and DNA originating from infected T cells [189,214–218]. However, more investigation is needed to determine the roles of HIV-1-induced MGCs in pathogenesis and whether these myeloid cell-derived MGCs may participate *in vivo* in HIV-1 cell-to-cell transmission, dissemination, and formation of persistent virus reservoirs in lymphoid and non-lymphoid tissues of infected patients.

### 1.5. Other Viruses

**Hepatitis C virus (HCV)** is an enveloped virus belonging to the *Hepacivirus* genus of the *Flaviridae* family [219], and its genome is a 10 kb monopartite, linear, positive single-stranded RNA. HCV primarily infects human hepatocytes, causing chronic hepatitis, hepatic cirrhosis, and hepatocellular carcinoma [220]. During replication, the viral RNA is translated into a polyprotein and then processed into three structural proteins, including the Envelope glycoproteins E1 and E2 which form a E1/E2 heterodimer, and seven nonstructural proteins [221]. The structural viral proteins form the capsid and envelope, while the non-structural proteins assume the enzymatic activities required for efficient replication [222]. After a facultative initial recognition of the cellular LDL receptor (LDL-R) at the surface of hepatocytes, HCV enters its target cells through clathrin-mediated endocytosis [223]. This process requires interaction of the envelope E2 glycoprotein with the cellular scavenger receptor B-I (SR-BI), triggering conformational changes for subsequent binding to the tetraspanin CD81 as co-receptor [224]. The tight junction proteins Claudin-1 and Occludin are also required for this process, but do not interact directly with the HCV envelope glycoproteins. E1 and E2 are N-glycosylated transmembrane proteins assembled as a heterodimer, stabilized by disulfide bonds on infected cells [225,226]. E2 first attaches to the SR-BI receptor, driving rearrangements of lipoproteins found associated with viral particles that expose the receptor binding sites of CD81 [227]. Only E2 has the ability to bind the receptors SR-BI and CD81 [228], while E1 is needed to trigger conformational modifications of the E1-E2 complex, allowing access of the E2 binding sites to SR-BI and CD81 [229]. Following the attachment step, virus particles and CD81-claudin-1 complexes are internalized through endocytosis [224]. The fusion between the viral particle and the early endosomal membranes is then governed by both E1 and E2 [230,231]. While endocytosis-mediated entry appears to be a predominant mode of infection for cell-free virions, some in vitro studies have shown that HCV could also infect target cells by cell-to-cell contacts, and this mode of transmission can sometimes involve cell-cell fusion, leading to the formation of syncytia [232–234]. The fusogenic activity of the HCV envelope glycoproteins for triggering cell-cell fusion was previously described [235]. The first study that described HCV-mediated cell-cell fusion and syncytia formation was performed on the human B lymphoblastoid TO-FE cell-line [236]. These authors showed that HCV-infected cells first form intercellular bridges, followed by cell-cell fusion leading to the formation of syncytia, and finally to cell lysis of this syncytia and virus release. Then, another group also observed the HCV-mediated formation of syncytia in vitro, using hepatocyte-derived carcinoma Huh7.5 cells transfected with HCV RNA [237], and this was related to the disruption of autophagy by HCV. Despite these few in vitro observations, evidences for HCV-mediated cell-cell fusion is still discussed [238], and there is actually very poor evidence in vivo for such HCV-triggered syncytium formation, questioning the relevance of these observations for HCV pathogenesis. To our knowledge, the presence of multinucleated giant cells has been finally reported in HCV-infected patients in only a single publication, in which Miccheli et al. [239] found multinucleated giant hepatocytes in 2.6% of 856 liver biopsies of HCV-infected patients. Of note, some of these patients were diagnosed as co-infected with HCV and HIV-1, but some others were only HCV-infected.

**Ebola viruses (EboVs)** belong to the *Filoviridae* family of enveloped viruses with a negative single-stranded RNA genome. Five species of EboVs have been identified and are mainly responsible for severe and often fatal hemorrhagic fevers in humans and non-human primates [240]. The Zaire EboV species is responsible for the outbreaks of lethal hemorrhagic fevers that took place in Africa during the last decade [241]. EboV can infect several cells types, including endothelial cells, hepatocytes, fibroblasts, dendritic cells, macrophages, and monocytes [240]. The virus binds to the host target cells using the viral glycoprotein GP, a heterodimer that consists in a receptor binding subunit GP1 and a fusion subunit GP2 [242]. No specific receptor for EboV has been identified to date, and GP1 can recognize and bind to several surface proteins on target cells, depending of the cell-lines, such as the C-type lectins DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) and hMGL (human N-acetylgalactosamine-specific C-type lectin), on macrophages and endothelial cells [243,244]; the tyrosine kinase receptor Axl on a large scale of primary mammalian cells except on B lymphocytes [245]; some  $\beta$ -integrins expressed at the

surface of the human kidney 293T cell-line [246]; and the T lymphocyte immunoglobulin and mucin domain 1 (TIM-1), mainly expressed on mucosal epithelial cells and also known as the cell surface receptor of the hepatitis A virus [247]. Following attachment through recognition of these cell surface molecules, the cell-free viral particle is internalized by micropinocytosis in early endosomal vesicles [248]. In late acidic endosomes, the GP1/GP2 heterodimers is cleaved through activation by cysteine proteases, cathepsins B and L, leading to conformational changes [249–251]. The receptor binding domain of GP1 is thus exposed to bind to the late endosomal protein Neimann-Pick 1 (NPC-1), a cholesterol transporter protein playing a critical role for virus entry, and thus triggers fusion with endosomal membranes through the fusion activity of the GP2 subunit [252]. The EboV core is finally released in the cytoplasm of the host cell to start viral replication.

In addition to this intracellular virus-endosome membrane fusion process, it was reported that EboV was also able to induce cell-cell fusion [253]. In this study, the authors co-cultured human HeLa epithelial cells transfected with the viral GP glycoprotein as virus-donor cells, and HeLa cells expressing the  $\beta$ -galactosidase reporter gene to detect the cytoplasmic exchanges following cell-cell fusion with target cells. In this co-culture system, the cell-cell fusion required optimal low pH expositions of the GP-expressing donor cells before co-culture [253]. Moreover, neutralizing antibodies targeting GP inhibited syncytia formation, showing the essential role of the GP protein for cell-cell fusion [253,254]. Similarly, Markosyan and colleagues [255] used COS7 cells, an African green monkey fibroblast cell-line, expressing the viral GP protein as a virus donor cell, and co-cultured with human HEK293T target cells, and confirmed that cell-cell fusion was mediated by the EboV GP through the same mechanism of EboV-induced endosomal fusion. After cleavage in endosomal compartments, the cell-cell fusion process requires recycling of the GP glycoproteins back to the cell surface. Since the cell-cell fusion induced by EboV has been poorly described, the mechanisms underlying this fusion process remain unclear and its role on viral transfer and spreading of Ebola virus in vivo remain uncertain, since no reports were published, to our knowledge, regarding the presence of EboV-induced syncytia in infected patients.

**Orthoreoviruses and Aquareoviruses** belong to the *Reoviridae* family and are non-enveloped viruses with a segmented double-strand RNA genome [256]. Interestingly, some members of these two genera are the only known examples of non-enveloped viruses able to induce syncytium formation in vitro, but also in vivo, to promote virus cell-to-cell spreading as a major determinant of virulence in infected hosts [257,258]. Syncytium formation is directly involved in direct virus cell-to-cell transmission, but it also participates in rapid release of intracellular progeny virions through subsequent disruption of syncytia and thus contributes to the pathogenicity of these viruses in their natural hosts. While Aquareoviruses displaying fusogenic properties to trigger syncytium formation have been isolated from fishes, mollusks, and crustaceans, Orthoreoviruses with fusogenic properties have been isolated from birds and reptiles, but also from mammals, including baboons and bats [256–259]. Moreover, several fusogenic Orthoreoviruses from bat origin have been identified in association with severe acute respiratory infections or meningo-encephalitis in humans [260–266], indicating that these viruses may emerge as zoonotic infections potentially responsible for future outbreaks. The intriguing property of these non-enveloped viruses to mediate syncytium formation for virus cell-to-cell transfer and dissemination between host target cells is related to expression of an original family of viral fusogens, the fusion-associated small transmembrane (FAST) proteins, initially discovered by Roy Duncan and colleagues [257–268]. Functionally, Reovirus FAST proteins largely differ from the 3 well-characterized classes of enveloped virus fusion proteins to trigger cell-cell fusion [1]. Fusogenic Aquareovirus and Orthoreoviruses genomes indeed contain an additional gene encoding for a FAST protein which is not found in the genomes of the non-fusogenic Reoviruses [257,258]. As non-structural, FAST proteins are not directly involved in virus entry and are non-essential for virus replication. Expressed at the cell surface of infected host cells and localizing at adherent cell-cell junctions, such as epithelial cells and fibroblasts, fusogenic Reovirus FAST proteins are sufficient to induce syncytium formation. FAST proteins are able to induce cell-cell fusion in a wide range of cell-types. Structurally, FAST are small integral transmembrane proteins, ranging from 100–200 amino acids in size, with a short N-terminal ectodomain which could function as a fusion peptide to insert

on the lipid bilayers of cell membranes, a single transmembrane domain, and a rather large C-terminal cytoplasmic tail of about 40 to 140 residues [257]. The three ecto-, transmembrane-, and cytoplasmic-domains of the FAST proteins are actively required for efficient cell-cell fusion, but how each domain is involved in the cell-cell fusion process to promote syncytium formation is still unclear, even if cellular cofactors have been involved in the FAST-induced cell-cell fusion process. While calcium-dependent cadherin proteins have been involved in the initial stage of cell-cell attachment [269], Annexin 1 (AX1) is required for post-fusion events, such as pore expansion [270]. In addition, both early and late stages of the cell-cell fusion process also involve active remodeling of the actin cytoskeleton [269].

## 2. Concluding Remarks

As reviewed here, it is evident that some viruses can use, at least in in vitro experimental systems, the fusogenic capacity of some viral proteins expressed at the surface of infected cells to trigger cell-cell fusion between infected virus-donor cells and neighboring target cells to form enlarged multinucleated cells and syncytia. The presence of such virus-induced syncytia has definitively been evidenced in host tissues and organs during the natural course of infections for several families of enveloped viruses, including major human virus pathogens, such as HIV-1, SARS-CoV-2, and Herpesviruses, as well as some members of the *Paramyxoviridae* (i.e., Measles virus and the respiratory syncytial virus). However, for most of these viruses, in vivo data regarding the role and functions of these syncytia in virus spreading, virulence, and virus persistence during the natural course of infection in their natural hosts are still discussed.

While all enveloped viruses express proteins displaying fusogenic features and should be theoretically able to induce cell-cell fusion, only certain enveloped viruses can trigger cell-cell fusion in tissues of infected hosts, indicating that host cellular pathways and mechanisms that maintain cell mobility, cellular adhesion, and cell membrane integrity certainly play specific roles in cell-cell fusion and syncytium formation, since fusion involves direct cell-to-cell contacts, cytoskeleton rearrangements, and the mixing of cellular contents, including membranes, cytoplasm, organelles, and nuclei. It is therefore critical to develop relevant in vitro experimental systems using primary host target cells for a better understanding of the cellular and molecular mechanisms, as well as the viral and cellular factors, that govern, and may control and modulate, virus-induced syncytium formation. Finally, further development of relevant experimental animal models should also help to in vivo investigation of the roles and functions of virus-induced syncytia in virus transmission and dissemination, as well as in virus evasion to innate and adaptive immunity, for a better understanding of their contribution to pathogenesis.

**Author Contributions:** H.L., M.H., M.W., L.B., J.B., M.X., and S.B.: writing original draft of the manuscript; J.B., L.B., and S.B.: editing the manuscript; S.B.: conceptualization and supervision of the review. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by INSERM, CNRS, Université of Paris, Agence Nationale de Recherche sur le SIDA et les Hépatites virales (ANRS).

**Acknowledgments:** Financial support is provided by INSERM, CNRS, and the University of Paris. The team is also funded by grants from ANRS. HL is supported by the University of Paris. MH and MX were supported by the China Scholarship Council. MW is supported by a grant from ANRS. LB was supported by grants from the Institut Pasteur International Network and the Chinese Academy of Sciences. J.B. was supported by a grant from Sidaction.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## References

1. Rey, F.A.; Lok, S.-M. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. *Cell* **2018**, *172*, 1319–1334, doi:10.1016/j.cell.2018.02.054.
2. Hoggan, M.D.; Roizman, B. The isolation and properties of a variant of herpes simplex producing multinucleated giant cells in monolayer cultures in the presence of antibody1. *Am. J. Epidemiol.* **1959**, *70*, 208–219, doi:10.1093/oxfordjournals.aje.a120071.
3. Sawitzky, D. Transmission, species specificity, and pathogenicity of Aujeszky's disease virus. *Viral Zoonoses Food Anim. Orig.* **1997**, *13*, 201–206, doi:10.1007/978-3-7091-6534-8\_19.
4. Lee, G.T.-Y.; Spear, P.G. Viral and cellular factors that influence cell fusion induced by herpes simplex virus. *Virology* **1980**, *107*, 402–414, doi:10.1016/0042-6822(80)90307-4.
5. Blank, H.; Burgoon, C.F.; Baldrige, G.D.; McCarthy, P.L.; Urbach, F. Cytologic smears in diagnosis of herpes simplex, herpes zoster, and varicella. *J. Am. Med. Assoc.* **1951**, *146*, 1410, doi:10.1001/jama.1951.63670150005012b.
6. Farhatullah, S.; Kaza, S.; Athmanathan, S.; Garg, P.; Reddy, S.B.; Sharma, S. Diagnosis of herpes simplex virus-1 keratitis using Giemsa stain, immunofluorescence assay, and polymerase chain reaction assay on corneal scrapings. *Br. J. Ophthalmol.* **2004**, *88*, 142–144, doi:10.1136/bjo.88.1.142.
7. Pritt, B.S.; Aubry, M.C. Histopathology of viral infections of the lung. *Semin. Diagn. Pathol.* **2017**, *34*, 510–517, doi:10.1053/j.semdp.2017.06.005.
8. Cole, N.L.; Grose, C. Membrane fusion mediated by herpesvirus glycoproteins: The paradigm of varicella-zoster virus. *Rev. Virol.* **2003**, *13*, 207–222, doi:10.1002/rmv.377.
9. Muggeridge, M.I.; Grantham, M.L.; Johnson, F.B. Identification of syncytial mutations in a clinical isolate of herpes simplex virus 2. *Virology* **2004**, *328*, 244–253, doi:10.1016/j.virol.2004.07.027.
10. Galitska, G.; Biolatti, M.; De Andrea, M.; Leone, A.; Coscia, A.; Bertolotti, L.; Ala, U.; Bertino, E.; Dell'Oste, V.; Landolfo, S. Biological relevance of Cytomegalovirus genetic variability in congenitally and postnatally infected children. *J. Clin. Virol.* **2018**, *108*, 132–140, doi:10.1016/j.jcv.2018.09.019.
11. Wheeler, C.E. Herpes simplex virus. Characteristics of a strain which produces unusually large multinucleated giant cells in tissue culture. *Arch Dermatol.* **1960**, *82*, 391–399.
12. Ejercito, P.M.; Kieff, E.D.; Roizman, B. Characterization of Herpes Simplex Virus Strains Differing in their Effects on Social Behaviour of Infected Cells. *J. Gen. Virol.* **1968**, *2*, 357–364, doi:10.1099/0022-1317-2-3-357.
13. Cassai, E.; Manservigi, R.; Corallini, A.; Terni, M. Plaque Dissociation of Herpes Simplex Viruses: Biochemical and Biological Characters of the Viral Variants. *Intervirology* **1975**, *6*, 212–223, doi:10.1159/000149476.
14. Read, G.S.; Person, S.; Keller, P.M. Genetic studies of cell fusion induced by herpes simplex virus type 1. *J. Virol.* **1980**, *35*, 105–113.
15. Spear, P.G.; Longnecker, R. Herpesvirus Entry: An Update. *J. Virol.* **2003**, *77*, 10179–10185, doi:10.1128/jvi.77.19.10179-10185.2003.
16. Connolly, S.A.; Jackson, J.O.; Jardetzky, T.S.; Longnecker, R. Fusing structure and function: A structural view of the herpesvirus entry machinery. *Nat. Rev. Microbiol.* **2011**, *9*, 369–381, doi:10.1038/nrmicro2548.
17. De Zarate, I.B.O.; Cantero-Aguilar, L.; Longo, M.; Berlioz-Torrent, C.; Rozenberg, F. Contribution of Endocytic Motifs in the Cytoplasmic Tail of Herpes Simplex Virus Type 1 Glycoprotein B to Virus Replication and Cell-Cell Fusion. *J. Virol.* **2007**, *81*, 13889–13903, doi:10.1128/jvi.01231-07.
18. Gerdts, V.; Beyer, J.; Lomniczi, B.; Mettenleiter, T.C. Pseudorabies Virus Expressing Bovine Herpesvirus 1 Glycoprotein B Exhibits Altered Neurotropism and Increased Neurovirulence. *J. Virol.* **2000**, *74*, 817–827, doi:10.1128/jvi.74.2.817-827.2000.
19. Atanasiu, D.; Whitbeck, J.C.; Cairns, T.M.; Reilly, B.; Cohen, G.H.; Eisenberg, R.J. Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 18718–18723, doi:10.1073/pnas.0707452104.
20. Stampfer, S.D.; Heldwein, E.E. Stuck in the middle: Structural insights into the role of the gH/gL heterodimer in herpesvirus entry. *Curr. Opin. Virol.* **2013**, *3*, 13–19, doi:10.1016/j.coviro.2012.10.005.
21. Heldwein, E.E. gH/gL supercomplexes at early stages of herpesvirus entry. *Curr. Opin. Virol.* **2016**, *18*, 1–8.
22. Weed, D.J.; Nicola, A.V. Herpes simplex virus Membrane Fusion. *Cell Biol. Herpes Viruses* **2017**, *223*, 29–47, doi:10.1007/978-3-319-53168-7\_2.



23. Fan, Q.; Longnecker, R.; Connolly, S.A. A Functional Interaction between Herpes Simplex Virus 1 Glycoprotein gH/gL Domains I and II and gD Is Defined by Using Alphaherpesvirus gH and gL Chimeras. *J. Virol.* **2015**, *89*, 7159–7169, doi:10.1128/jvi.00740-15.
24. Di Giovine, P.; Settembre, E.C.; Bhargava, A.K.; Luftig, M.A.; Lou, H.; Cohen, G.H.; Eisenberg, R.J.; Krummenacher, C.; Carfi, A. Structure of Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor Nectin-1. *PLoS Pathog.* **2011**, *7*, e1002277, doi:10.1371/journal.ppat.1002277.
25. Montgomery, R.I.; Warner, M.S.; Lum, B.J.; Spear, P.G. Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family. *Cell* **1996**, *87*, 427–436, doi:10.1016/s0092-8674(00)81363-x.
26. Tiwari, V.; O'Donnell, C.; Copeland, R.J.; Scarlett, T.; Liu, J.; Shukla, D. Soluble 3-O-sulfated heparan sulfate can trigger herpes simplex virus type 1 entry into resistant Chinese hamster ovary (CHO-K1) cells. *J. Gen. Virol.* **2007**, *88*, 1075–1079, doi:10.1099/vir.0.82476-0.
27. Ryckman, B.J.; Jarvis, M.A.; Drummond, D.D.; Nelson, J.A.; Johnson, D.C. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. *J. Virol.* **2006**, *80*, 710–722.
28. Ciferri, C.; Chandramouli, S.; Norais, N.; Settembre, E.C.; Carfi, A.; Donnarumma, D.; Nikitin, P.A.; Cianfrocco, M.A.; Gerrein, R.; Feire, A.L.; et al. Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 1767–1772, doi:10.1073/pnas.1424818112.
29. Jasirwan, C.O.M.; Furusawa, Y.; Tang, H.-M.; Maeki, T.; Mori, Y. Human herpesvirus-6A gQ1 and gQ2 are critical for human CD46 usage. *Microbiol. Immunol.* **2014**, *58*, 22–30, doi:10.1111/1348-0421.12110.
30. Santoro, F.; Kennedy, P.E.; Locatelli, G.; Malnati, M.S.; Berger, E.A.; Lusso, P. CD46 Is a Cellular Receptor for Human Herpesvirus 6. *Cell* **1999**, *99*, 817–827, doi:10.1016/s0092-8674(00)81678-5.
31. Tang, H.; Serada, S.; Kawabata, A.; Ota, M.; Hayashi, E.; Naka, T.; Yamanishi, K.; Mori, Y. CD134 is a cellular receptor specific for human herpesvirus-6B entry. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 9096–9099, doi:10.1073/pnas.1305187110.
32. Li, Q.; Spriggs, M.K.; Kovats, S.; Turk, S.M.; Comeau, M.R.; Nepom, B.; Hutt-Fletcher, L.M. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. *J. Virol.* **1997**, *71*, 4657–4662.
33. Chesnokova, L.S.; Hutt-Fletcher, L.M. Fusion of Epstein-Barr virus with epithelial cells can be triggered by alphavbeta5 in addition to alphavbeta6 and alphavbeta8, and integrin binding triggers a conformational change in glycoproteins gHgL. *J. Virol.* **2011**, *85*, 13214–13223.
34. Sarfo, A.; Starkey, J.; Mellinger, E.; Zhang, D.; Chadha, P.; Carmichael, J.; Wills, J.W. The UL21 Tegument Protein of Herpes Simplex Virus 1 Is Differentially Required for the Syncytial Phenotype. *J. Virol.* **2017**, *91*, e01161-17, doi:10.1128/jvi.01161-17.
35. Dingwell, K.S.; Brunetti, C.R.; Hendricks, R.L.; Tang, Q.; Tang, M.; Rainbow, A.J.; Johnson, D.C. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. *J. Virol.* **1994**, *68*, 834–845.
36. Scherer, W.F.; Syverton, J.T. The viral range in vitro of a malignant human epithelial cell (strain HeLa, Gel). I. Multiplication of herpes simplex, pseudorabies, and vaccinia viruses. *Am. J. Pathol.* **1954**, *30*, 1057–1073.
37. Gray, A.; Tokumaru, T.; Scott, T.F.M. Different cytopathogenic effects observed in HeLa cells infected with herpes simplex virus. *Arch. Gesamte Virusforsch.* **1958**, *8*, 59–76, doi:10.1007/bf01242313.
38. Tognon, M.; Manservigi, R.; Cavrini, V.; Campadelli-Fiume, G. Characterization of a herpes simplex virus type 1 mutant resistant to benzhydrazone, a selective inhibitor of herpesvirus glycosylation. *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 2440–2443, doi:10.1073/pnas.81.8.2440.
39. Bzik, D.J.; Fox, B.A.; DeLuca, N.; Person, S. Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: Mutations affecting rate of virus entry and cell fusion. *Virology* **1984**, *137*, 185–190.
40. Cai, W.H.; Gu, B.; Person, S. Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. *J. Virol.* **1988**, *62*, 2596–2604.
41. Engel, J.P.; Boyer, E.P.; Goodman, J.L. Two Novel Single Amino Acid Syncytial Mutations in the Carboxy Terminus of Glycoprotein B of Herpes Simplex Virus Type 1 Confer a Unique Pathogenic Phenotype. *Virology* **1993**, *192*, 112–120, doi:10.1006/viro.1993.1013.

42. Turner, A.; Bruun, B.; Minson, T.; Browne, H. Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. *J. Virol.* **1998**, *72*, 873–875.
43. Davis-Poynter, N.; Bell, S.; Minson, T.; Browne, H. Analysis of the contributions of herpes simplex virus type 1 membrane proteins to the induction of cell-cell fusion. *J. Virol.* **1994**, *68*, 7586–7590, doi:10.1128/jvi.68.11.7586-7590.1994.
44. Avitabile, E.; Lombardi, G.; Campadelli-Fiume, G. Herpes Simplex Virus Glycoprotein K, but Not Its Syncytial Allele, Inhibits Cell-Cell Fusion Mediated by the Four Fusogenic Glycoproteins, gD, gB, gH, and gL. *J. Virol.* **2003**, *77*, 6836–6844, doi:10.1128/jvi.77.12.6836-6844.2003.
45. Ren, Y.; Bell, S.; Zenner, H.L.; Lau, S.-Y.K.; Crump, C.M. Glycoprotein M is important for the efficient incorporation of glycoprotein H–L into herpes simplex virus type 1 particles. *J. Gen. Virol.* **2012**, *93*, 319–329, doi:10.1099/vir.0.035444-0.
46. Crump, C.M.; Bruun, B.; Bell, S.; Pomeranz, L.E.; Minson, T.; Browne, H.M. Alphaherpesvirus glycoprotein M causes the relocalization of plasma membrane proteins. *J. Gen. Virol.* **2004**, *85*, 3517–3527, doi:10.1099/vir.0.80361-0.
47. Chouljenko, V.N.; Iyer, A.V.; Chowdhury, S.; Kim, J.; Kousoulas, K.G. The Herpes Simplex Virus Type 1 UL20 Protein and the Amino Terminus of Glycoprotein K (gK) Physically Interact with gB. *J. Virol.* **2010**, *84*, 8596–8606, doi:10.1128/jvi.00298-10.
48. Han, J.; Chadha, P.; Starkey, J.L.; Wills, J.W. Function of glycoprotein E of herpes simplex virus requires coordinated assembly of three tegument proteins on its cytoplasmic tail. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 19798–19803, doi:10.1073/pnas.1212900109.
49. Chatterjee, S.; Koga, J.; Whitley, R.J. A Role for Herpes Simplex Virus Type 1 Glycoprotein E in Induction of Cell Fusion. *J. Gen. Virol.* **1989**, *70*, 2157–2162, doi:10.1099/0022-1317-70-8-2157.
50. Terry-Allison, T.; Montgomery, R.I.; Whitbeck, J.C.; Xu, R.; Cohen, G.H.; Eisenberg, R.J.; Spear, P.G. HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion. *J. Virol.* **1998**, *72*, 5802–5810.
51. Terry-Allison, T.; Montgomery, R.I.; Warner, M.S.; Geraghty, R.J.; Spear, P.G. Contributions of gD receptors and glycosaminoglycan sulfation to cell fusion mediated by herpes simplex virus 1. *Virus Res.* **2001**, *74*, 39–45, doi:10.1016/s0168-1702(00)00244-6.
52. Shieh, M.T.; Spear, P.G. Herpesvirus-induced cell fusion that is dependent on cell surface heparan sulfate or soluble heparin. *J. Virol.* **1994**, *68*, 1224–1228.
53. Satoh, T.; Arai, J.; Suenaga, T.; Wang, J.; Kogure, A.; Uehori, J.; Arase, N.; Shiratori, I.; Tanaka, S.; Kawaguchi, Y.; et al. PILRALpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. *Cell* **2008**, *132*, 935–944.
54. Carmichael, J.C.; Yokota, H.; Craven, R.C.; Schmitt, A.; Wills, J.W. The HSV-1 mechanisms of cell-to-cell spread and fusion are critically dependent on host PTP1B. *PLoS Pathog.* **2018**, *14*, e1007054, doi:10.1371/journal.ppat.1007054.
55. Gerna, G.; Baldanti, F.; Revello, M. Pathogenesis of human cytomegalovirus infection and cellular targets. *Hum. Immunol.* **2004**, *65*, 381–386, doi:10.1016/j.humimm.2004.02.009.
56. Compton, T. Receptors and immune sensors: The complex entry path of human cytomegalovirus. *Trends Cell Biol.* **2004**, *14*, 5–8, doi:10.1016/j.tcb.2003.10.009.
57. Vanarsdall, A.L.; Johnson, D.C. Human cytomegalovirus entry into cells. *Curr. Opin. Virol.* **2012**, *2*, 37–42, doi:10.1016/j.coviro.2012.01.001.
58. Waldman, W.J.; Sneddon, J.M.; Stephens, R.E.; Roberts, W.H. Enhanced endothelial cytopathogenicity induced by a cytomegalovirus strain propagated in endothelial cells. *J. Med. Virol.* **1989**, *28*, 223–230.
59. Wilkinson, G.W.G.; Davison, A.J.; Tomasec, P.; Fielding, C.A.; Aicheler, R.; Murrell, I.; Seirafian, S.; Wang, E.C.Y.; Weekes, M.; Lehner, P.J.; et al. Human cytomegalovirus: Taking the strain. *Med. Microbiol. Immunol.* **2015**, *204*, 273–284, doi:10.1007/s00430-015-0411-4.
60. Murrell, I.; Bedford, C.; Ladell, K.; Miners, K.L.; Price, D.A.; Tomasec, P.; Wilkinson, G.W.G.; Stanton, R.J. The pentameric complex drives immunologically covert cell–cell transmission of wild-type human cytomegalovirus. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 6104–6109, doi:10.1073/pnas.1704809114.
61. Vanarsdall, A.L.; Ryckman, B.J.; Chase, M.C.; Johnson, D.C. Human Cytomegalovirus Glycoproteins gB and gH/gL Mediate Epithelial Cell-Cell Fusion When Expressed either in cis or in trans. *J. Virol.* **2008**, *82*, 11837–11850, doi:10.1128/jvi.01623-08.

62. Tugizov, S.; Navarro, D.; Paz, P.; Wang, Y.; Qadri, I.; Pereira, L. Function of Human Cytomegalovirus Glycoprotein B: Syncytium Formation in Cells Constitutively Expressing gB Is Blocked by Virus-Neutralizing Antibodies. *Virology* **1994**, *201*, 263–276, doi:10.1006/viro.1994.1291.
63. Navarro, D.; Paz, P.; Tugizov, S.; Topp, K.; La Vail, J.; Pereira, L. Glycoprotein B of Human Cytomegalovirus Promotes Virion Penetration into Cells, Transmission of Infection from Cell to Cell, and Fusion of Infected Cells. *Virology* **1993**, *197*, 143–158, doi:10.1006/viro.1993.1575.
64. Wille, P.T.; Wisner, T.W.; Ryckman, B.; Johnson, D.C. Human Cytomegalovirus (HCMV) Glycoprotein gB Promotes Virus Entry In Trans Acting as the Viral Fusion Protein Rather than as a Receptor-Binding Protein. *mBio* **2013**, *4*, e00332–13, doi:10.1128/mbio.00332-13.
65. Tang, J.; Frascaroli, G.; Lebbink, R.J.; Ostermann, E.; Brune, W. Human cytomegalovirus glycoprotein B variants affect viral entry, cell fusion, and genome stability. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 18021–18030, doi:10.1073/pnas.1907447116.
66. Reuter, N.; Kropff, B.; Schneiderbanger, J.K.; Alt, M.; Krawczyk, A.; Sinzger, C.; Winkler, T.H.; Britt, W.J.; Mach, M.; Thomas, M. Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB. *J. Virol.* **2020**, *94*, doi:10.1128/jvi.01276-20.
67. Paterson, D.A.; Dyer, A.P.; Milne, R.S.; Sevilla-Reyes, E.; Gompels, U.A. A Role for Human Cytomegalovirus Glycoprotein O (gO) in Cell Fusion and a New Hypervariable Locus. *Virology* **2002**, *293*, 281–294, doi:10.1006/viro.2001.1274.
68. Aguilar, H.C.; Iorio, R.M. Henipavirus Membrane Fusion and Viral Entry. *Curr. Top. Microbiol. Immunol.* **2012**, *359*, 79–94, doi:10.1007/82\_2012\_200.
69. Domurat, F.; Roberts, J.N.J.; Walsh, E.E.; Dagan, R. Respiratory Syncytial Virus Infection of Human Mononuclear Leukocytes in Vitro and in Vivo. *J. Infect. Dis.* **1985**, *152*, 895–902, doi:10.1093/infdis/152.5.895.
70. Herschke, F.; Plumet, S.; Duhon, T.; Azocar, O.; Druelle, J.; Laine, D.; Wild, T.F.; Rabourdin-Combe, C.; Gerlier, D.; Valentin, H. Cell-Cell Fusion Induced by Measles Virus Amplifies the Type I Interferon Response. *J. Virol.* **2007**, *81*, 12859–12871, doi:10.1128/jvi.00078-07.
71. Okada, Y. Sendai virus-induced cell fusion. In *Methods in Enzymology*; Elsevier: Amsterdam, The Netherlands, 1993; Volume 221, pp. 18–41.
72. Koethe, S.; Avota, E.; Schneider-Schaulies, S. Measles Virus Transmission from Dendritic Cells to T Cells: Formation of Synapse-Like Interfaces Concentrating Viral and Cellular Components. *J. Virol.* **2012**, *86*, 9773–9781, doi:10.1128/jvi.00458-12.
73. Ferreira, C.S.A.; Frenzke, M.; Leonard, V.H.J.; Welstead, G.G.; Richardson, C.D.; Cattaneo, R. Measles Virus Infection of Alveolar Macrophages and Dendritic Cells Precedes Spread to Lymphatic Organs in Transgenic Mice Expressing Human Signaling Lymphocytic Activation Molecule (SLAM, CD150). *J. Virol.* **2010**, *84*, 3033–3042, doi:10.1128/jvi.01559-09.
74. Aref, S.; Bailey, K.; Fielding, A.K. Measles to the Rescue: A Review of Oncolytic Measles Virus. *Viruses* **2016**, *8*, 294, doi:10.3390/v8100294.
75. Watanabe, S.; Shirogane, Y.; Suzuki, S.O.; Ikegame, S.; Koga, R.; Yanagi, Y. Mutant Fusion Proteins with Enhanced Fusion Activity Promote Measles Virus Spread in Human Neuronal Cells and Brains of Suckling Hamsters. *J. Virol.* **2013**, *87*, 2648–2659, doi:10.1128/jvi.02632-12.
76. Lin, L.-T.; Richardson, C.D. The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein. *Viruses* **2016**, *8*, 250, doi:10.3390/v8090250.
77. Tatsuo, H.; Ono, N.; Tanaka, K.; Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. *Nature* **2000**, *406*, 893–897, doi:10.1038/35022579.
78. Mühlebach, M.D.; Mateo, M.; Ramachandran, S.; McCray, P.B.; Cichutek, K.; Von Messling, V.; Lopez, M.; Cattaneo, R.; Sinn, P.L.; Prüfer, S.; et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. *Nature* **2011**, *480*, 530–533, doi:10.1038/nature10639.
79. Navaratnarajah, C.K.; Leonard, V.H.J.; Cattaneo, R. Measles Virus Glycoprotein Complex Assembly, Receptor Attachment, and Cell Entry. *Curr. Top. Microbiol. Immunol.* **2009**, *329*, 59–76, doi:10.1007/978-3-540-70523-9\_4.
80. Russell, C.J.; Luque, L.E. The structural basis of paramyxovirus invasion. *Trends Microbiol.* **2006**, *14*, 243–246, doi:10.1016/j.tim.2006.04.004.
81. Ludlow, M.; McQuaid, S.; Milner, D.; De Swart, R.L.; Duprex, W.P. Pathological consequences of systemic measles virus infection. *J. Pathol.* **2015**, *235*, 253–265, doi:10.1002/path.4457.

82. Enders, J.F.; Peebles, T.C. Propagation in Tissue Cultures of Cytopathogenic Agents from Patients with Measles. *Exp. Biol. Med.* **1954**, *86*, 277–286, doi:10.3181/00379727-86-21073.
83. White, R.G.; Boyd, J.F. The effect of measles on the thymus and other lymphoid tissues. *Clin. Exp. Immunol.* **1973**, *13*, 343–357.
84. Gripenberg, U.; Forbes, C. Extensive cytological damage caused by measles in African children. *J. Med. Genet.* **1974**, *11*, 171–176, doi:10.1136/jmg.11.2.171.
85. Kimura, A.; Tosaka, K.; Nakao, T. Measles Rash. I. Light and Electron Microscopic Study of Skin Eruptions. *Arch. Virol.* **1975**, *47*, 295–307.
86. Osunkoya, B.O.; Ukaejiofo, E.O.; Ajayi, O.; Akinyemi, A.A. Evidence that circulating lymphocytes act as vehicles or viraemia in measles. *West Afr. J. Med.* **1990**, *9*, 35–39.
87. Fugier-Vivier, I.; Servet-Delprat, C.; Rivaille, P.; Rissoan, M.-C.; Liu, Y.-J.; Rabourdin-Combe, C. Measles Virus Suppresses Cell-mediated Immunity by Interfering with the Survival and Functions of Dendritic and T Cells. *J. Exp. Med.* **1997**, *186*, 813–823, doi:10.1084/jem.186.6.813.
88. Seya, T.; Kurita, M.; Iwata, K.; Yanagi, Y.; Tanaka, K.; Shida, K.; Hatanaka, M.; Matsumoto, M.; Jun, S.; Hirano, A.; et al. The CD46 transmembrane domain is required for efficient formation of measles-virus-mediated syncytium. *Biochem. J.* **1997**, *322*, 135–144, doi:10.1042/bj3220135.
89. Takeuchi, K.; Miyajima, N.; Nagata, N.; Takeda, M.; Tashiro, M. Wild-type measles virus induces large syncytium formation in primary human small airway epithelial cells by a SLAM(CD150)-independent mechanism. *Virus Res.* **2003**, *94*, 11–16, doi:10.1016/s0168-1702(03)00117-5.
90. Kelly, J.T.; Human, S.; Alderman, J.; Jobe, F.; Logan, L.; Rix, T.; Gonçalves-Carneiro, D.; Leung, C.; Thakur, N.; Birch, J.; et al. BST2/Tetherin Overexpression Modulates Morbillivirus Glycoprotein Production to Inhibit Cell-Cell Fusion. *Viruses* **2019**, *11*, 692, doi:10.3390/v11080692.
91. Hinz, A.; Miguet, N.; Natrajan, G.; Usami, Y.; Yamanaka, H.; Renesto, P.; Hartlieb, B.; McCarthy, A.A.; Simorre, J.-P.; Göttlinger, H.; et al. Structural Basis of HIV-1 Tethering to Membranes by the BST-2/Tetherin Ectodomain. *Cell Host Microbe* **2010**, *7*, 314–323, doi:10.1016/j.chom.2010.03.005.
92. Borchers, A.T.; Chang, C.; Gershwin, M.E.; Gershwin, L.J. Respiratory Syncytial Virus—A Comprehensive Review. *Clin. Rev. Allergy Immunol.* **2013**, *45*, 331–379, doi:10.1007/s12016-013-8368-9.
93. Johnson, J.E.; Gonzales, R.A.; Olson, S.J.; Wright, P.F.; Graham, B.S. The histopathology of fatal untreated human respiratory syncytial virus infection. *Mod. Pathol.* **2007**, *20*, 108–119, doi:10.1038/modpathol.3800725.
94. Wright, P.F.; Ikizler, M.R.; Gonzales, R.A.; Carroll, K.N.; Johnson, J.E.; Werkhaven, J.A. Growth of Respiratory Syncytial Virus in Primary Epithelial Cells from the Human Respiratory Tract. *J. Virol.* **2005**, *79*, 8651–8654, doi:10.1128/jvi.79.13.8651-8654.2005.
95. Heminway, B.; Yu, Y.; Tanaka, Y.; Perrine, K.; Gustafson, E.; Bernstein, J.; Galinski, M. Analysis of Respiratory Syncytial Virus F, G, and SH Proteins in Cell Fusion. *Virology* **1994**, *200*, 801–805, doi:10.1006/viro.1994.1245.
96. MartínezI.; Melero, J.A. Binding of human respiratory syncytial virus to cells: Implication of sulfated cell surface proteoglycans. *J. Gen. Virol.* **2000**, *81*, 2715–2722, doi:10.1099/0022-1317-81-11-2715.
97. Feldman, S.A.; Audet, S.; Beeler, J.A. The Fusion Glycoprotein of Human Respiratory Syncytial Virus Facilitates Virus Attachment and Infectivity via an Interaction with Cellular Heparan Sulfate. *J. Virol.* **2000**, *74*, 6442–6447, doi:10.1128/jvi.74.14.6442-6447.2000.
98. Krzyzaniak, M.A.; Zumstein, M.T.; Gerez, J.A.; Picotti, P.; Helenius, A. Host Cell Entry of Respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F Protein. *PLoS Pathog.* **2013**, *9*, e1003309, doi:10.1371/journal.ppat.1003309.
99. San-Juan-Vergara, H.; Sampayo-Escobar, V.; Reyes, N.; Cha, B.; Pacheco-Lugo, L.; Wong, T.; Peeples, M.E.; Collins, P.L.; Castaño, M.E.; Mohapatra, S.S. Cholesterol-Rich Microdomains as Docking Platforms for Respiratory Syncytial Virus in Normal Human Bronchial Epithelial Cells. *J. Virol.* **2012**, *86*, 1832–1843, doi:10.1128/jvi.06274-11.
100. Cifuentes-Muñoz, N.; Chang, A. To assemble or not to assemble: The changing rules of pneumovirus transmission. *Virus Res.* **2019**, *265*, 68–73, doi:10.1016/j.virusres.2019.03.002.
101. Gower, T.L.; Peeples, M.E.; Collins, P.L.; Graham, B.S. RhoA Is Activated During Respiratory Syncytial Virus Infection. *Virology* **2001**, *283*, 188–196, doi:10.1006/viro.2001.0891.
102. Gower, T.L.; Pastey, M.K.; Peeples, M.E.; Collins, P.L.; McCurdy, L.H.; Hart, T.K.; Guth, A.; Johnson, T.R.; Graham, B.S. RhoA Signaling Is Required for Respiratory Syncytial Virus-Induced Syncytium Formation and Filamentous Virion Morphology. *J. Virol.* **2005**, *79*, 5326–5336, doi:10.1128/jvi.79.9.5326-5336.2005.

103. Kim, J.-G.; Islam, R.; Cho, J.Y.; Jeong, H.; Cap, K.-C.; Park, Y.; Hossain, A.J.; Park, J.-B. Regulation of RhoA GTPase and various transcription factors in the RhoA pathway. *J. Cell. Physiol.* **2018**, *233*, 6381–6392, doi:10.1002/jcp.26487.
104. De Albuquerque, L.P.; Patriota, L.L.D.S.; Gonzatto, V.; Pontual, E.V.; Paiva, P.M.G.; Napoleão, T.H. Coronavirus Spike (S) Protein: A Brief Review on Structure-Function Relationship, Host Receptors, and Role in Cell Infection. *Adv. Res.* **2020**, 116–124, doi:10.9734/air/2020/v21i930240.
105. Hussain, S.; Pan, J.; Chen, Y.; Yang, Y.; Xu, J.; Peng, Y.; Wu, Y.; Li, Z.; Zhu, Y.; Tien, P.; et al. Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus. *J. Virol.* **2005**, *79*, 5288–5295, doi:10.1128/jvi.79.9.5288-5295.2005.
106. Woo, P.C.Y.; Lau, S.K.P.; Lam, C.S.F.; Lau, C.C.Y.; Tsang, A.K.L.; Lau, J.H.N.; Bai, R.; Teng, J.L.L.; Tsang, C.C.C.; Wang, M.; et al. Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and Deltacoronavirus. *J. Virol.* **2012**, *86*, 3995–4008, doi:10.1128/jvi.06540-11.
107. Jafarzadeh, A.; Chauhan, P.; Saha, B.; Jafarzadeh, S.; Nemati, M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. *Life Sci.* **2020**, *257*, 118102, doi:10.1016/j.lfs.2020.118102.
108. McFee, R. Human pathogen coronaviruses—An overview. *Disease* **2020**, *66*, 101066, doi:10.1016/j.disamonth.2020.101066.
109. Battagello, D.S.; Dragunas, G.; Klein, M.O.; Ayub, A.L.P.; Velloso, F.J.; Correa, R.G. Unpuzzling COVID-19: Tissue-Related Signaling Pathways Associated with SARS-CoV-2 Infection and Transmission. *Clin. Sci. Lond.* **2020**, *134*, 2137–2160.
110. Pillaiyar, T.; Meenakshisundaram, S.; Manickam, M. Recent discovery and development of inhibitors targeting coronaviruses. *Drug Discov. Today* **2020**, *25*, 668–688, doi:10.1016/j.drudis.2020.01.015.
111. Kim, H.-R.; Oem, J.-K. Surveillance of Avian Coronaviruses in Wild Bird Populations of Korea. *J. Wildl. Dis.* **2014**, *50*, 964–968, doi:10.7589/2013-11-298.
112. Bai, D.; Fang, L.; Xia, S.; Ke, W.; Wang, J.; Wu, X.; Fang, P.; Xiao, S. Porcine deltacoronavirus (PDCoV) modulates calcium influx to favor viral replication. *Virology* **2020**, *539*, 38–48, doi:10.1016/j.virol.2019.10.011.
113. Sainz, B.; Rausch, J.M.; Gallaher, W.R.; Garry, R.F.; Wimley, W.C. Identification and Characterization of the Putative Fusion Peptide of the Severe Acute Respiratory Syndrome-Associated Coronavirus Spike Protein. *J. Virol.* **2005**, *79*, 7195–7206, doi:10.1128/jvi.79.11.7195-7206.2005.
114. Heald-Sargent, T.; Gallagher, T. Ready, Set, Fuse! The Coronavirus Spike Protein and Acquisition of Fusion Competence. *Viruses* **2012**, *4*, 557–580, doi:10.3390/v4040557.
115. Belouzard, S.; Millet, J.K.; Licitra, B.N.; Whittaker, G.R. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein. *Viruses* **2012**, *4*, 1011–1033, doi:10.3390/v4061011.
116. Bosch, B.J.; Van Der Zee, R.; De Haan, C.A.M.; Rottier, P.J.M. The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex. *J. Virol.* **2003**, *77*, 8801–8811, doi:10.1128/jvi.77.16.8801-8811.2003.
117. Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. In *Coronaviruses: Methods and Protocols*; Maier, H.J.B., Erica Britton, P., Eds.; Springer: New York, NY, USA, 2015; Volume 1282, pp. 1–23.
118. Belouzard, S.; Chu, V.C.; Whittaker, G.R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 5871–5876, doi:10.1073/pnas.0809524106.
119. Kahn, J.S.; McIntosh, K. History and Recent Advances in Coronavirus Discovery. *Pediatr. Infect. Dis. J.* **2005**, *24*, S223–S227, doi:10.1097/01.inf.0000188166.17324.60.
120. Buchrieser, J.; Dufloo, J.; Hubert, M.; Monel, B.; Planas, D.; Rajah, M.M.; Planchais, C.; Porrot, F.; Guivel-Benhassine, F.; Van der Werf, S.; et al. Syncytia Formation by SARS-CoV-2-Infected Cells. *EMBO J.* **2020**, *39*, e106267, doi: 10.15252/embj.2020106267.
121. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **2020**, *181*, 271–280.e8, doi:10.1016/j.cell.2020.02.052.
122. Ng, D.L.; Al Hosani, F.; Keating, M.K.; Gerber, S.I.; Jones, T.L.; Metcalfe, M.G.; Tong, S.; Tao, Y.; Alami, N.N.; Haynes, L.M.; et al. Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal

- Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. *Am. J. Pathol.* **2016**, *186*, 652–658, doi:10.1016/j.ajpath.2015.10.024.
123. Stadlmann, S.; Hein-Kuhnt, R.; Singer, G. Viropathic multinuclear syncytial giant cells in bronchial fluid from a patient with COVID-19. *J. Clin. Pathol.* **2020**, *73*, 607–608, doi:10.1136/jclinpath-2020-206657.
124. Qian, Z.; Dominguez, S.R.; Holmes, K.V. Role of the Spike Glycoprotein of Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia Formation. *PLoS ONE* **2013**, *8*, e76469.
125. Jin, Y.; Yang, H.; Ji, W.; Wu, W.; Chen, S.; Zhang, W.; Duan, G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses* **2020**, *12*, 372, doi:10.3390/v12040372.
126. Bradley, B.T.; Maioli, H.; Johnston, R.; Chaudhry, I.; Fink, S.L.; Xu, H.; Najafian, B.; Deutsch, G.; Lacy, J.M.; Williams, T.; et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: A case series. *Lancet* **2020**, *396*, 320–332, doi:10.1016/s0140-6736(20)31305-2.
127. Bussani, R.; Schneider, E.; Zentilin, L.; Collesi, C.; Ali, H.; Braga, L.; Volpe, M.C.; Colliva, A.; Zanconati, F.; Berlot, G.; et al. Persistence of Viral RNA, Pneumocyte Syncytia and Thrombosis Are Hallmarks of Advanced COVID-19 Pathology. *SSRN Electron. J.* **2020**, 103104, doi:10.2139/ssrn.3654168.
128. Mason, R.J. Pathogenesis of COVID-19 from a cell biology perspective. *Eur. Respir. J.* **2020**, *55*, 2000607, doi:10.1183/13993003.00607-2020.
129. Tian, S.; Hu, W.; Niu, L.; Liu, H.; Xu, H.; Xiao, S. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. *J. Thorac. Oncol.* **2020**, *15*, 700–704, doi:10.1016/j.jtho.2020.02.010.
130. Wang, C.; Xie, J.; Zhao, L.; Fei, X.; Zhang, H.; Tan, Y.; Nie, X.; Zhou, L.; Liu, Z.; Ren, Y.; et al. Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients. *EBioMedicine* **2020**, *57*, 102833, doi:10.1016/j.ebiom.2020.102833.
131. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* **2020**, *8*, 420–422, doi:10.1016/s2213-2600(20)30076-x.
132. Zhu, N.; Wang, W.; Liu, Z.; Liang, C.; Wang, W.; Ye, F.; Huang, B.; Zhao, L.; Wang, H.; Zhou, W.; et al. Morphogenesis and Cytopathic Effect of SARS-CoV-2 Infection in Human Airway Epithelial Cells. *Nat. Commun.* **2020**, *11*, 3910.
133. Musarrat, F.; Chouljenko, V.; Dahal, A.; Nabi, R.; Chouljenko, T.; Jois, S.D.; Kousoulas, K. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARS-CoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. *J. Med. Virol.* **2020**, *92*, 2087–2095, doi:10.1002/jmv.25985.
134. Raj, V.S.; Mou, H.; Thiel, V.; Drosten, C.; Rottier, P.J.M.; Osterhaus, A.D.M.E.; Bosch, B.-J.; Haagmans, B.; Smits, S.L.; Dekkers, D.H.W.; et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* **2013**, *495*, 251–254, doi:10.1038/nature12005.
135. Gierer, S.; Bertram, S.; Kaup, F.; Wrensch, F.; Heurich, A.; Krämer-Kühl, A.; Welsch, K.; Winkler, M.; Meyer, B.; Drosten, C.; et al. The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies. *J. Virol.* **2013**, *87*, 5502–5511, doi:10.1128/jvi.00128-13.
136. Yuan, Y.; Cao, D.; Zhang, Y.; Ma, J.; Qi, J.; Wang, Q.; Lu, G.; Wu, Y.; Yan, J.; Shi, Y.; et al. Cryo-EM Structures of MERS-CoV and SARS-CoV Spike Glycoproteins Reveal the Dynamic Receptor Binding Domains. *Nat. Commun.* **2017**, *8*, 15092.
137. Chan, J.F.-W.; Chan, K.-H.; Choi, G.K.-Y.; To, K.K.-W.; Tse, H.; Cai, J.-P.; Yeung, M.L.; Cheng, V.C.-C.; Chen, H.; Che, X.-Y.; et al. Differential Cell Line Susceptibility to the Emerging Novel Human Betacoronavirus 2c EMC/2012: Implications for Disease Pathogenesis and Clinical Manifestation. *J. Infect. Dis.* **2013**, *207*, 1743–1752, doi:10.1093/infdis/jit123.
138. Shirato, K.; Kawase, M.; Matsuyama, S. Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2. *J. Virol.* **2013**, *87*, 12552–12561, doi:10.1128/jvi.01890-13.
139. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **2020**, *579*, 270–273, doi:10.1038/s41586-020-2012-7.
140. Chu, H.; Chan, J.F.-W.; Yuen, T.T.-T.; Shuai, H.; Yuan, S.; Wang, Y.; Hu, B.; Yip, C.C.-Y.; Tsang, J.O.-L.; Huang, X.; et al. Comparative Tropism, Replication Kinetics, and Cell Damage Profiling of SARS-CoV-2

- and SARS-CoV with Implications for Clinical Manifestations, Transmissibility, and Laboratory Studies of COVID-19: An Observational Study. *Lancet Microbe* **2020**, *1*, e14–e23.
141. Tang, D.; Comish, P.; Kang, R. The hallmarks of COVID-19 disease. *PLoS Pathog.* **2020**, *16*, e1008536, doi:10.1371/journal.ppat.1008536.
  142. Simmons, G.; Bertram, S.; Pöhlmann, S.; Glowacka, I.; Steffen, I.; Chaipan, C.; Agudelo, J.; Lu, K.; Rennekamp, A.J.; Hofmann, H.; et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion. *Virology* **2011**, *413*, 265–274, doi:10.1016/j.virol.2011.02.020.
  143. Coutard, B.; Valle, C.; De Lamballerie, X.; Canard, B.; Seidah, N.; Decroly, E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antivir. Res.* **2020**, *176*, 104742, doi:10.1016/j.antiviral.2020.104742.
  144. Chen, Y.; Liu, Q.; Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J. Med. Virol.* **2020**, *92*, 418–423, doi:10.1002/jmv.25681.
  145. Chakraborty, H.; Bhattacharjya, S. Mechanistic Insights of Host Cell Fusion of SARS-CoV-1 and SARS-CoV-2 from Atomic Resolution Structure and Membrane Dynamics. *Biophys. Chem.* **2020**, *265*, 106438.
  146. Wrapp, D.; Wang, N.; Corbett, K.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **2020**, *367*, 1260–1263, doi:10.1126/science.abb2507.
  147. Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell Entry Mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 11727–11734.
  148. Hoffmann, M.; Kleine-Weber, H.; Pöhlmann, S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol. Cell* **2020**, *78*, 779–784.e5.
  149. Xia, S.; Liu, M.; Wang, C.; Xu, W.; Lan, Q.; Feng, S.; Qi, F.; Bao, L.; Du, L.; Liu, S.; et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res.* **2020**, *30*, 343–355.
  150. Ou, X.; Liu, Y.; Lei, X.; Li, P.; Mi, D.; Ren, L.; Guo, L.; Guo, R.; Chen, T.; Hu, J.; et al. Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity with SARS-CoV. *Nat. Commun.* **2020**, *11*, 1620.
  151. Bozzo, C.P.; Nchioua, R.; Volcic, M.; Wettstein, L.; Weil, T.; Krüger, J.; Heller, S.; Conzelmann, C.; Müller, J.; Gross, R.; et al. IFITM Proteins Promote SARS-CoV-2 Infection of Human Lung Cells. *bioRxiv* **2020**, doi:10.1101/2020.08.18.255935.
  152. Craigie, R. Retroviral DNA Integration. *Mobile DNA II* **2002**, *76*, 613–630, doi:10.1128/9781555817954.ch25.
  153. Gessain, A.; Vernant, J.; Maurs, L.; Barin, F.; Gout, O.; Calender, A.; De Thé, G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. *Lancet* **1985**, *326*, 407–410, doi:10.1016/s0140-6736(85)92734-5.
  154. Osame, M.; Usuku, K.; Izumo, S.; Ijichi, N.; Amitani, H.; Igata, A.; Matsumoto, M.; Tara, M. HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY. *Lancet* **1986**, *327*, 1031–1032, doi:10.1016/s0140-6736(86)91298-5.
  155. Poiesz, B.J.; Ruscetti, F.W.; Gazdar, A.F.; Bunn, P.A.; Minna, J.D.; Gallo, R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc. Natl. Acad. Sci. USA* **1980**, *77*, 7415–7419, doi:10.1073/pnas.77.12.7415.
  156. Yoshida, M.; Seiki, M.; Yamaguchi, K.; Takatsuki, K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 2534–2537, doi:10.1073/pnas.81.8.2534.
  157. Gessain, A.; Cassar, O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. *Front. Microbiol.* **2012**, *3*, 388, doi:10.3389/fmicb.2012.00388.
  158. Dutartre, H.; Clavière, M.; Journo, C.; Mahieux, R. Cell-Free versus Cell-to-Cell Infection by Human Immunodeficiency Virus Type 1 and Human T-Lymphotropic Virus Type 1: Exploring the Link among Viral Source, Viral Trafficking, and Viral Replication. *J. Virol.* **2016**, *90*, 7607–7617, doi:10.1128/jvi.00407-16.
  159. Piñón, J.D.; Klasse, P.J.; Jassal, S.R.; Welson, S.; Weber, J.; Brighty, D.W.; Sattentau, Q.J. Human T-Cell Leukemia Virus Type 1 Envelope Glycoprotein gp46 Interacts with Cell Surface Heparan Sulfate Proteoglycans. *J. Virol.* **2003**, *77*, 9922–9930, doi:10.1128/jvi.77.18.9922-9930.2003.
  160. Ghez, D.; Lepelletier, Y.; Lambert, S.; Fourneau, J.-M.; Blot, V.; Janvier, S.; Arnulf, B.; Van Endert, P.M.; Heveker, N.; Pique, C.; et al. Neuropilin-1 Is Involved in Human T-Cell Lymphotropic Virus Type 1 Entry. *J. Virol.* **2006**, *80*, 6844–6854, doi:10.1128/jvi.02719-05.

161. Manel, N.; Kim, F.J.; Kinet, S.; Taylor, N.; Sitbon, M.; Battini, J.-L. The Ubiquitous Glucose Transporter GLUT-1 Is a Receptor for HTLV. *Cell* **2003**, *115*, 449–459, doi:10.1016/s0092-8674(03)00881-x.
162. Daenke, S.; Booth, S. Molecular Mechanisms Affecting HTLV Type 1-Dependent Fusion at the Cell Membrane: Implications for Inhibiting Viral Transmission. *AIDS Res. Hum. Retrovir.* **2000**, *16*, 1731–1736, doi:10.1089/08892220050193227.
163. Ho, D.D.; Rota, T.R.; Hirsch, M.S. Infection of human endothelial cells by human T-lymphotropic virus type I. *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 7588–7590, doi:10.1073/pnas.81.23.7588.
164. Paré, M.-È.; Gauthier, S.; Landry, S.; Sun, J.; Legault, É.; Leclerc, D.; Tanaka, Y.; Marriott, S.J.; Tremblay, M.J.; Barbeau, B. A new sensitive and quantitative HTLV-I-mediated cell fusion assay in T cells. *Virology* **2005**, *338*, 309–322, doi:10.1016/j.virol.2005.05.012.
165. Blot, V.; Delamarre, L.; Perugi, F.; Pham, D.; Benichou, S.; Benarous, R.; Hanada, T.; Chishti, A.H.; Dokh elar, M.-C.; Pique, C. Human Dlg protein binds to the envelope glycoproteins of human T-cell leukemia virus type 1 and regulates envelope mediated cell-cell fusion in T lymphocytes. *J. Cell Sci.* **2004**, *117*, 3983–3993, doi:10.1242/jcs.01266.
166. Hildreth, J.E.; Subramaniam, A.; Hampton, R.A. Human T-cell lymphotropic virus type 1 (HTLV-1)-induced syncytium formation mediated by vascular cell adhesion molecule-1: Evidence for involvement of cell adhesion molecules in HTLV-1 biology. *J. Virol.* **1997**, *71*, 1173–1180, doi:10.1128/jvi.71.2.1173-1180.1997.
167. Nejmeddine, M.; Bangham, C.R.M. The HTLV-1 Virological Synapse. *Viruses* **2010**, *2*, 1427–1447, doi:10.3390/v2071427.
168. Valentin, H.; Lemasson, I.; Hamaia, S.; Cass e, H.; K onig, S.; Devaux, C.; Gazzolo, L. Transcriptional activation of the vascular cell adhesion molecule-1 gene in T lymphocytes expressing human T-cell leukemia virus type 1 Tax protein. *J. Virol.* **1997**, *71*, 8522–8530, doi:10.1128/jvi.71.11.8522-8530.1997.
169. Mazurov, D.; Ilinskaya, A.; Heidecker, G.; Lloyd, P.; Derse, D. Quantitative Comparison of HTLV-1 and HIV-1 Cell-to-Cell Infection with New Replication Dependent Vectors. *PLoS Pathog.* **2010**, *6*, e1000788, doi:10.1371/journal.ppat.1000788.
170. Pique, C.; Lagaudri ere-Gesbert, C.; Delamarre, L.; Rosenberg, A.R.; Conjeaud, H.; Dokh elar, M.-C. Interaction of CD82 Tetraspanin Proteins with HTLV-1 Envelope Glycoproteins Inhibits Cell-to-Cell Fusion and Virus Transmission. *Virology* **2000**, *276*, 455–465, doi:10.1006/viro.2000.0538.
171. Pais-Correia, A.-M.; Sachse, M.; Guadagnini, S.; Robbiati, V.; Lasserre, R.; Gessain, A.; Gout, O.; Alcover, A.; Thoulouze, M.-I. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. *Nat. Med.* **2010**, *16*, 83–89, doi:10.1038/nm.2065.
172. Stevenson, M. HIV-1 pathogenesis. *Nat. Med.* **2003**, *9*, 853–860, doi:10.1038/nm0703-853.
173. Joseph, S.B.; Swanstrom, R. The evolution of HIV-1 entry phenotypes as a guide to changing target cells. *J. Leukoc. Biol.* **2018**, *103*, 421–431, doi:10.1002/jlb.2ri0517-200r.
174. Bracq, L.; Xie, M.; Benichou, S.; Bouchet, J. Mechanisms for Cell-to-Cell Transmission of HIV-1. *Front. Immunol.* **2018**, *9*, 260, doi:10.3389/fimmu.2018.00260.
175. Hildreth, J.; Orentas, R. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. *Science* **1989**, *244*, 1075–1078, doi:10.1126/science.2543075.
176. Lifson, J.D.; Feinberg, M.B.; Reyes, G.R.; Rabin, L.; Banapour, B.; Chakrabarti, S.; Moss, B.; Wong-Staal, F.; Steimer, K.S.; Engleman, E.G. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. *Nat. Cell Biol.* **1986**, *323*, 725–728, doi:10.1038/323725a0.
177. Schols, D.; Pauwels, R.; Baba, M.; Desmyter, J.; De Clercq, E. Syncytium Formation and Destruction of Bystander CD4+ Cells Cocultured with T Cells Persistently Infected with Human Immunodeficiency Virus as Demonstrated by Flow Cytometry. *J. Gen. Virol.* **1989**, *70*, 2397–2408, doi:10.1099/0022-1317-70-9-2397.
178. Sodroski, J.; Goh, W.C.; Rosen, C.; Campbell, K.; Haseltine, W.A. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. *Nat. Cell Biol.* **1986**, *322*, 470–474, doi:10.1038/322470a0.
179. Sylwester, A.; Wessels, D.; Anderson, S.A.; Warren, R.Q.; Shutt, D.C.; Kennedy, R.C.; Soll, D.R. HIV-induced syncytia of a T cell line form single giant pseudopods and are motile. *J. Cell Sci.* **1993**, *106*, 941–953.
180. Soll, D.R.; Kennedy, R.C. The Role of T Cell Motility and Cytoskeletal Reorganization in HIV-Induced Syncytium Formation. *AIDS Res. Hum. Retrovir.* **1994**, *10*, 325–327, doi:10.1089/aid.1994.10.325.
181. Sylwester, A.; Murphy, S.; Shutt, D.; Soll, D.R. HIV-induced T cell syncytia are self-perpetuating and the primary cause of T cell death in culture. *J. Immunol.* **1997**, *158*, 3996–4007.



182. Carr, J.M.; Hocking, H.; Li, P.; Burrell, C. Rapid and Efficient Cell-to-Cell Transmission of Human Immunodeficiency Virus Infection from Monocyte-Derived Macrophages to Peripheral Blood Lymphocytes. *Virology* **1999**, *265*, 319–329, doi:10.1006/viro.1999.0047.
183. Chen, P.; Hubner, W.; Spinelli, M.A.; Chen, B.K. Predominant Mode of Human Immunodeficiency Virus Transfer between T Cells Is Mediated by Sustained Env-Dependent Neutralization-Resistant Virological Synapses. *J. Virol.* **2007**, *81*, 12582–12595, doi:10.1128/jvi.00381-07.
184. Sourisseau, M.; Sol-Foulon, N.; Porrot, F.; Blanchet, F.; Schwartz, O. Inefficient Human Immunodeficiency Virus Replication in Mobile Lymphocytes. *J. Virol.* **2007**, *81*, 1000–1012, doi:10.1128/jvi.01629-06.
185. Moore, J.P.; Ho, D.D. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. *AIDS* **1995**, *9*, S117–S136.
186. Orenstein, J.M. In Vivo Cytolysis and Fusion of Human Immunodeficiency Virus Type 1-Infected Lymphocytes in Lymphoid Tissue. *J. Infect. Dis.* **2000**, *182*, 338–342, doi:10.1086/315640.
187. Murooka, T.T.; Deruaz, M.; Marangoni, F.; Vrbanc, V.D.; Seung, E.; Von Andrian, U.H.; Tager, A.M.; Luster, A.D.; Mempel, T.R. HIV-infected T cells are migratory vehicles for viral dissemination. *Nature* **2012**, *490*, 283–287, doi:10.1038/nature11398.
188. Symeonides, M.; Murooka, T.T.; Bellfy, L.N.; Roy, N.H.; Mempel, T.R.; Thali, M. HIV-1-Induced Small T Cell Syncytia Can Transfer Virus Particles to Target Cells through Transient Contacts. *Viruses* **2015**, *7*, 6590–6603, doi:10.3390/v7122959.
189. Frankel, S.S.; Wenig, B.M.; Burke, A.P.; Mannan, P.; Thompson, L.D.; Abbondanzo, S.L.; Nelson, A.M.; Pope, M.; Steinman, R.M. Replication of HIV-1 in Dendritic Cell-Derived Syncytia at the Mucosal Surface of the Adenoid. *Science* **1996**, *272*, 115–117, doi:10.1126/science.272.5258.115.
190. Granelli-Piperno, A.; Pope, M.; Inaba, K.; Steinman, R.M. Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 10944–10948, doi:10.1073/pnas.92.24.10944.
191. Bracq, L.; Xie, M.; Lambelé, M.; Vu, L.-T.; Matz, J.; Schmitt, A.; Delon, J.; Zhou, P.; Randriamampita, C.; Bouchet, J.; et al. T Cell-Macrophage Fusion Triggers Multinucleated Giant Cell Formation for HIV-1 Spreading. *J. Virol.* **2017**, *91*, e01237-17, doi:10.1128/jvi.01237-17.
192. Xie, M.; Leroy, H.; Mascarau, R.; Woottum, M.; Dupont, M.; Ciccone, C.; Schmitt, A.; Raynaud-Messina, B.; Vérollet, C.; Bouchet, J.; et al. Cell-to-Cell Spreading of HIV-1 in Myeloid Target Cells Escapes SAMHD1 Restriction. *mBio* **2019**, *10*, doi:10.1128/mbio.02457-19.
193. Costiniuk, C.T.; Jenabian, M.-A. Cell-to-cell transfer of HIV infection: Implications for HIV viral persistence. *J. Gen. Virol.* **2014**, *95*, 2346–2355, doi:10.1099/vir.0.069641-0.
194. Costiniuk, C.T.; Jenabian, M.-A. The lungs as anatomical reservoirs of HIV infection. *Rev. Med. Virol.* **2014**, *24*, 35–54, doi:10.1002/rmv.1772.
195. Tan, J.; Sattentau, Q.J. The HIV-1-containing macrophage compartment: A perfect cellular niche? *Trends Microbiol.* **2013**, *21*, 405–412, doi:10.1016/j.tim.2013.05.001.
196. Watters, S.A.; Mlcochova, P.; Gupta, R.K. Macrophages: The Neglected Barrier to Eradication. *Curr. Opin. Infect. Dis.* **2013**, *26*, 561–566.
197. Ganor, Y.; Real, F.; Sennepin, A.; Dutertre, C.-A.; Prevedel, L.; Xu, L.; Tudor, D.; Charmeteanu, B.; Couedel-Courteille, A.; Marion, S.; et al. HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy. *Nat. Microbiol.* **2019**, *4*, 633–644, doi:10.1038/s41564-018-0335-z.
198. Teo, I.; Veryard, C.; Barnes, H.; An, S.F.; Jones, M.; Lantos, P.L.; Luthert, P.; Shaunak, S. Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: Association with dementia and multinucleated giant cells in the brains of patients with AIDS. *J. Virol.* **1997**, *71*, 2928–2933, doi:10.1128/jvi.71.4.2928-2933.1997.
199. Burdo, T.H.; Lackner, A.; Williams, K.C. Monocyte/macrophages and their role in HIV neuropathogenesis. *Immunol. Rev.* **2013**, *254*, 102–113, doi:10.1111/imr.12068.
200. Fischer-Smith, T.; Bell, C.; Croul, S.; Lewis, M.; Rappaport, J. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: Lessons from human and nonhuman primate studies. *J. NeuroVirol.* **2008**, *14*, 318–326, doi:10.1080/13550280802132857.
201. Geny, C.; Gherardi, R.; Boudes, P.; Lionnet, F.; Cesaro, P.; Gray, F. Multifocal multinucleated giant cell myelitis in an AIDS patient. *Neuropathol. Appl. Neurobiol.* **1991**, *17*, 157–162, doi:10.1111/j.1365-2990.1991.tb00707.x.

202. González-Scarano F.; Martín-García, J. The neuropathogenesis of AIDS. *Nat. Rev. Immunol.* **2005**, *5*, 69–81, doi:10.1038/nri1527.
203. Gras, G.; Kaul, M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. *Retrovirology* **2010**, *7*, 1–11, doi:10.1186/1742-4690-7-30.
204. Harbison, C.; Zhuang, K.; Gettie, A.; Blanchard, J.; Knight, H.; Didier, P.; Cheng-Mayer, C.; Westmoreland, S.V. Giant cell encephalitis and microglial infection with mucosally transmitted simian-human immunodeficiency virus SHIVSF162P3N in rhesus macaques. *J. NeuroVirol.* **2014**, *20*, 62–72, doi:10.1007/s13365-013-0229-z.
205. Koenig, S.; Gendelman, H.E.; Orenstein, J.M.; Canto, M.C.D.; Pezeshkpour, G.H.; Yungbluth, M.; Janotta, F.; Aksamit, A.; Martin, M.A.; Fauci, A.S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. *Science* **1986**, *233*, 1089–1093, doi:10.1126/science.3016903.
206. Frankel, S.S.; Tenner-Racz, K.; Racz, P.; Wenig, B.M.; Hansen, C.H.; Heffner, D.; Nelson, A.M.; Pope, M.; Steinman, R.M. Active replication of HIV-1 at the lymphoepithelial surface of the tonsil. *Am. J. Pathol.* **1997**, *151*, 89–96.
207. Orenstein, J.M.; Wahl, S.M. The Macrophage Origin of the HIV-Expressing Multinucleated Giant Cells in Hyperplastic Tonsils and Adenoids. *Ultrastruct. Pathol.* **1999**, *23*, 79–91, doi:10.1080/019131299281734.
208. Vicandi, B.; Jiménez-Heffernan, J.A.; López-Ferrer, P.; Patrón, M.; Gamallo, C.; Colmenero, C.; Viguer, J.M. HIV-1 (p24)-Positive Multinucleated Giant Cells in HIV-Associated Lymphoepithelial Lesion of the Parotid Gland. *Acta Cytol.* **1999**, *43*, 247–251, doi:10.1159/000330987.
209. Vérollet, C.; Zhang, Y.M.; Le Cabec, V.; Mazzolini, J.; Charrière, G.M.; Labrousse, A.; Bouchet, J.; Medina, I.; Biessen, E.; Niedergang, F.; et al. HIV-1 Nef Triggers Macrophage Fusion in a p61Hck- and Protease-Dependent Manner. *J. Immunol.* **2010**, *184*, 7030–7039, doi:10.4049/jimmunol.0903345.
210. Raynaud-Messina, B.; Bracq, L.; Dupont, M.; Souriant, S.; Usmani, S.M.; Proag, A.; Pingris, K.; Soldan, V.; Thibault, C.; Capilla, F.; et al. Bone degradation machinery of osteoclasts: An HIV-1 target that contributes to bone loss. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E2556–E2565, doi:10.1073/pnas.1713370115.
211. Vérollet, C.; Souriant, S.; Bonnaud, E.; Jolicoeur, P.; Raynaud-Messina, B.; Kinnaer, C.; Fourquaux, I.; Imle, A.; Benichou, S.; Fackler, O.T.; et al. HIV-1 reprograms the migration of macrophages. *Blood* **2015**, *125*, 1611–1622, doi:10.1182/blood-2014-08-596775.
212. Dargent, J.-L.; Lespagnard, L.; Kornreich, A.; Hermans, P.; Clumeck, N.; Verhest, A. HIV-Associated Multinucleated Giant Cells in Lymphoid Tissue of the Waldeyer's Ring: A Detailed Study. *Mod. Pathol.* **2000**, *13*, 1293–1299, doi:10.1038/modpathol.3880237.
213. Lewin-Smith, M.; Wahl, S.M.; Orenstein, J.M. Human immunodeficiency virus-rich multinucleated giant cells in the colon: A case report with transmission electron microscopy, immunohistochemistry, and in situ hybridization. *Mod. Pathol.* **1999**, *12*, 75–81.
214. Calantone, N.; Wu, F.; Loré, K.; Douek, D.C.; Estes, J.D.; Hirsch, V.M.; Brenchley, J.M.; Klase, Z.; Deleage, C.; Perkins, M.; et al. Tissue Myeloid Cells in SIV-Infected Primates Acquire Viral DNA through Phagocytosis of Infected T Cells. *Immunity* **2014**, *41*, 493–502, doi:10.1016/j.immuni.2014.08.014.
215. DiNapoli, S.R.; Ortiz, A.M.; Wu, F.; Matsuda, K.; Twigg, H.L.; Hirsch, V.M.; Knox, K.; Brenchley, J.M. Tissue-resident macrophages can contain replication-competent virus in antiretroviral-naive, SIV-infected Asian macaques. *JCI Insight* **2017**, *2*, e91214, doi:10.1172/jci.insight.91214.
216. Pope, M.; Betjes, M.; Romani, N.; Hirmand, H.; Cameron, P.; Hoffman, L.; Gezelter, S.; Schuler, G.; Steinman, R. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. *Cell* **1994**, *78*, 389–398, doi:10.1016/0092-8674(94)90418-9.
217. Piguet, V.; Steinman, R.M. The interaction of HIV with dendritic cells: Outcomes and pathways. *Trends Immunol.* **2007**, *28*, 503–510, doi:10.1016/j.it.2007.07.010.
218. Frankel, S.S.; Steinman, R.M.; Michael, N.L.; Kim, S.R.; Bhardwaj, N.; Pope, M.; Louder, M.K.; Ehrenberg, P.K.; Parren, P.W.H.I.; Burton, D.R.; et al. Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells. *J. Virol.* **1998**, *72*, 9788–9794, doi:10.1128/jvi.72.12.9788-9794.1998.
219. Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* **1989**, *244*, 359–362, doi:10.1126/science.2523562.
220. D'Souza, S.; Lau, K.C.; Coffin, C.S.; Patel, T.R. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. *World J. Gastroenterol.* **2020**, *26*, 5759–5783, doi:10.3748/wjg.v26.i38.5759.

221. Dubuisson, J.; Rey, F.A.; Moradpour, D.; Pawlotsky, J.-M. Structural biology of hepatitis C virus. *Hepatology* **2004**, *39*, 5–19, doi:10.1002/hep.20032.
222. Chevaliez, S.; Pawlotsky, J.-M. HCV Genome and Life Cycle. In *Hepatitis C Viruses: Genomes and Molecular Biology*; Tan, S.-L., Ed.; Horizon Bioscience: Norfolk, UK, 2006.
223. Blanchard, E.; Belouzard, S.; Goueslain, L.; Wakita, T.; Dubuisson, J.; Wychowski, C.; Rouillé, Y. Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis. *J. Virol.* **2006**, *80*, 6964–6972, doi:10.1128/jvi.00024-06.
224. Farquhar, M.J.; Hu, K.; Harris, H.J.; Davis, C.; Brimacombe, C.L.; Fletcher, S.J.; Baumert, T.F.; Rappoport, J.Z.; Balfe, P.; McKeating, J.A. Hepatitis C Virus Induces CD81 and Claudin-1 Endocytosis. *J. Virol.* **2012**, *86*, 4305–4316, doi:10.1128/jvi.06996-11.
225. Vieyres, G.; Thomas, X.; Descamps, V.; Duverlie, G.; Patel, A.H.; Dubuisson, J. Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus. *J. Virol.* **2010**, *84*, 10159–10168, doi:10.1128/jvi.01180-10.
226. Helle, F.; Vieyres, G.; Elkrief, L.; Popescu, C.-I.; Wychowski, C.; Descamps, V.; Castelain, S.; Roingeard, P.; Duverlie, G.; Dubuisson, J. Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions. *J. Virol.* **2010**, *84*, 11905–11915, doi:10.1128/jvi.01548-10.
227. Thi, V.L.D.; Granier, C.; Zeisel, M.B.; Guérin, M.; Mancip, J.; Granio, O.; Penin, F.; Lavillette, D.; Bartenschlager, R.; Baumert, T.F.; et al. Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps. *J. Biol. Chem.* **2012**, *287*, 31242–31257, doi:10.1074/jbc.m112.365924.
228. Patel, A.H.; Wood, J.; Penin, F.; Dubuisson, J.; McKeating, J.A. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: Analysis of regions critical for glycoprotein aggregation and CD81 binding. *J. Gen. Virol.* **2000**, *81*, 2873–2883, doi:10.1099/0022-1317-81-12-2873.
229. Wahid, A.; Helle, F.; Descamps, V.; Duverlie, G.; Penin, F.; Dubuisson, J. Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein. *J. Virol.* **2012**, *87*, 1605–1617, doi:10.1128/jvi.02659-12.
230. Meertens, L.; Bertaux, C.; Dragic, T. Hepatitis C Virus Entry Requires a Critical Postinternalization Step and Delivery to Early Endosomes via Clathrin-Coated Vesicles. *J. Virol.* **2006**, *80*, 11571–11578, doi:10.1128/jvi.01717-06.
231. Douam, F.; Lavillette, D.; Cosset, F.-L. Chapter Three—The Mechanism of HCV Entry into Host Cells. In *Progress in Molecular Biology and Translational Science*; Klasse, P.J., Ed.; The Molecular Basis of Viral Infection; Academic Press: Cambridge, MA, USA, 2015; Volume 129, pp. 63–107.
232. Brimacombe, C.L.; Grove, J.; Meredith, L.W.; Hu, K.; Syder, A.J.; Flores, M.V.; Timpe, J.M.; Krieger, S.E.; Baumert, T.F.; Tellinghuisen, T.L.; et al. Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission. *J. Virol.* **2010**, *85*, 596–605, doi:10.1128/jvi.01592-10.
233. Catanese, M.T.; Loureiro, J.; Jones, C.T.; Dorner, M.; Von Hahn, T.; Rice, C. Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission. *J. Virol.* **2013**, *87*, 8282–8293, doi:10.1128/jvi.01102-13.
234. Timpe, J.M.; Stamataki, Z.; McKeating, J.A.; Jennings, A.; Hu, K.; Farquhar, M.J.; Harris, H.J.; Schwarz, A.; Desombere, I.; Roels, G.L.; et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. *Hepatology* **2008**, *47*, 17–24, doi:10.1002/hep.21959.
235. Takikawa, S.; Ishii, K.; Aizaki, H.; Suzuki, T.; Asakura, H.; Matsuura, Y.; Miyamura, T. Cell Fusion Activity of Hepatitis C Virus Envelope Proteins. *J. Virol.* **2000**, *74*, 5066–5074, doi:10.1128/.74.11.5066-5074.2000.
236. Serafino, A.; Valli, M.B.; Andreola, F.; Crema, A.; Ravagnan, G.; Bertolini, L.; Carloni, G. Suggested role of the Golgi apparatus and endoplasmic reticulum for crucial sites of hepatitis C virus replication in human lymphoblastoid cells infected in vitro. *J. Med. Virol.* **2003**, *70*, 31–41, doi:10.1002/jmv.10367.
237. Sir, D.; Chen, W.-L.; Choi, J.; Wakita, T.; Yen, T.B.; Ou, J.-H.J. Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. *Hepatology* **2008**, *48*, 1054–1061, doi:10.1002/hep.22464.
238. Carloni, G.; Crema, A.; Valli, M.B.; Ponzetto, A.; Clementi, M. HCV Infection by Cell-to-Cell Transmission: Choice or Necessity? *Curr. Mol. Med.* **2012**, *12*, 83–95.
239. Micchelli, S.T.L.; Thomas, D.; Boitnott, J.K.; Torbenson, M. Hepatic giant cells in hepatitis C virus (HCV) mono-infection and HCV/HIV co-infection. *J. Clin. Pathol.* **2008**, *61*, 1058–1061, doi:10.1136/jcp.2008.058560.

240. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. *Lancet* **2011**, *377*, 849–862, doi:10.1016/s0140-6736(10)60667-8.
241. Baseler, L.; Chertow, D.S.; Johnson, K.M.; Feldmann, H.; Morens, D.M. The Pathogenesis of Ebola Virus Disease. *Annu. Rev. Pathol. Mech. Dis.* **2017**, *12*, 387–418, doi:10.1146/annurev-pathol-052016-100506.
242. Lee, J.E.; Saphire, E.O. Ebolavirus Glycoprotein Structure and Mechanism of Entry. *Future Virol.* **2009**, *4*, 621–635.
243. Simmons, G.; Reeves, J.D.; Doms, R.W.; Bates, P.; Pöhlmann, S.; Grogan, C.C.; Vandenberghe, L.H.; Baribaud, F.; Whitbeck, J.C.; Burke, E.; et al. DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells. *Virology* **2003**, *305*, 115–123, doi:10.1006/viro.2002.1730.
244. Takada, A.; Fujioka, K.; Tsuiji, M.; Morikawa, A.; Higashi, N.; Ebihara, H.; Kobasa, D.; Feldmann, H.; Irimura, T.; Kawaoka, Y. Human Macrophage C-Type Lectin Specific for Galactose and N-Acetylgalactosamine Promotes Filovirus Entry. *J. Virol.* **2004**, *78*, 2943–2947, doi:10.1128/jvi.78.6.2943-2947.2004.
245. Shimojima, M.; Takada, A.; Ebihara, H.; Neumann, G.; Fujioka, K.; Irimura, T.; Jones, S.; Feldmann, H.; Kawaoka, Y. Tyro3 Family-Mediated Cell Entry of Ebola and Marburg Viruses. *J. Virol.* **2006**, *80*, 10109–10116, doi:10.1128/jvi.01157-06.
246. Takada, A.; Watanabe, S.; Ito, H.; Okazaki, K.; Kida, H.; Kawaoka, Y. Downregulation of Beta1 Integrins by Ebola Virus Glycoprotein: Implication for Virus Entry. *Virology* **2000**, *278*, 20–26.
247. Kondratowicz, A.S.; Lennemann, N.J.; Sandersfeld, L.M.; Quinn, K.; Weller, M.L.; McCray, P.B.; Chiorini, J.A.; Maury, W.; Sinn, P.L.; Davey, R.A.; et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 8426–8431, doi:10.1073/pnas.1019030108.
248. Saeed, M.F.; Kolokoltsov, A.A.; Albrecht, T.; Davey, R. Cellular Entry of Ebola Virus Involves Uptake by a Macropinocytosis-Like Mechanism and Subsequent Trafficking through Early and Late Endosomes. *PLoS Pathog.* **2010**, *6*, e1001110, doi:10.1371/journal.ppat.1001110.
249. Brecher, M.; Schornberg, K.L.; Delos, S.E.; Fusco, M.L.; Saphire, E.O.; White, J.M. Cathepsin Cleavage Potentiates the Ebola Virus Glycoprotein To Undergo a Subsequent Fusion-Relevant Conformational Change. *J. Virol.* **2012**, *86*, 364–372, doi:10.1128/jvi.05708-11.
250. Chandran, K.; Sullivan, N.J.; Felbor, U.; Whelan, S.P.; Cunningham, J.M. Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection. *Science* **2005**, *308*, 1643–1645, doi:10.1126/science.1110656.
251. Hood, C.L.; Abraham, J.; Boyington, J.C.; Leung, K.; Kwong, P.D.; Nabel, G.J. Biochemical and Structural Characterization of Cathepsin L-Processed Ebola Virus Glycoprotein: Implications for Viral Entry and Immunogenicity. *J. Virol.* **2010**, *84*, 2972–2982, doi:10.1128/jvi.02151-09.
252. Carette, J.E.; Raaben, M.; Cin, P.D.; Dye, J.M.; Whelan, S.P.J.; Chandran, K.; Brummelkamp, T.R.; Wong, A.C.; Herbert, A.S.; Obernosterer, G.; et al. Ebola virus entry requires the cholesterol transporter Niemann–Pick C1. *Nature* **2011**, *477*, 340–343, doi:10.1038/nature10348.
253. BärS.; Takada, A.; Kawaoka, Y.; Alizon, M. Detection of Cell-Cell Fusion Mediated by Ebola Virus Glycoproteins. *J. Virol.* **2006**, *80*, 2815–2822, doi:10.1128/jvi.80.6.2815-2822.2006.
254. Ito, H.; Watanabe, S.; Sanchez, A.; Whitt, M.A.; Kawaoka, Y. Mutational Analysis of the Putative Fusion Domain of Ebola Virus Glycoprotein. *J. Virol.* **1999**, *73*, 8907–8912, doi:10.1128/jvi.73.10.8907-8912.1999.
255. Markosyan, R.M.; Miao, C.; Zheng, Y.-M.; Melikyan, G.B.; Liu, S.-L.; Cohen, F.S. Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger. *PLoS Pathog.* **2016**, *12*, e1005373, doi:10.1371/journal.ppat.1005373.
256. Dermody, T.S.; Parker, J.S.L.; Sherry, B. *Fields Virology*; Knipe, D.M., Howley, P.M., Racaniello, B.R., Eds.; Lippincott Williams and Wilkens: Philadelphia, PA, USA, 2013; pp. 1304–1346.
257. Duncan, R. Fusogenic Reoviruses and Their Fusion-Associated Small Transmembrane (FAST) Proteins. *Annu. Rev. Virol.* **2019**, *6*, 341–363, doi:10.1146/annurev-virology-092818-015523.
258. Ciechonska, M.; Duncan, R. Reovirus FAST proteins: Virus-encoded cellular fusogens. *Trends Microbiol.* **2014**, *22*, 715–724, doi:10.1016/j.tim.2014.08.005.
259. Leland, M.M.; Hubbard, G.B.; Sentmore, H.T.; Soike, K.F.; Hilliard, J.K. Outbreak of Orthoreovirus-induced meningoencephalomyelitis in baboons. *Comp. Med.* **2000**, *50*, 199–205.

260. Cheng, P.; Lau, C.S.; Lai, A.; Ho, E.; Leung, P.; Chan, F.; Wong, A.; Lim, W. A novel reovirus isolated from a patient with acute respiratory disease. *J. Clin. Virol.* **2009**, *45*, 79–80, doi:10.1016/j.jcv.2009.03.001.
261. Chua, K.; Cramer, G.; Hyatt, A.; Yu, M.; Tompang, M.; Rosli, J.; McEachern, J.; Cramer, S.; Kumarasamy, V.; Eaton, B.; et al. A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 11424–11429, doi:10.3410/f.1088847.541958.
262. Chua, K.B.; Voon, K.; Cramer, G.; Tan, H.S.; Rosli, J.; McEachern, J.A.; Suluraju, S.; Yu, M.; Wang, L.-F. Identification and Characterization of a New Orthoreovirus from Patients with Acute Respiratory Infections. *PLoS ONE* **2008**, *3*, e3803, doi:10.1371/journal.pone.0003803.
263. Chua, K.B.; Voon, K.; Yu, M.; Keniscope, C.; Rasid, K.A.; Wang, L. Investigation of a Potential Zoonotic Transmission of Orthoreovirus Associated with Acute Influenza-Like Illness in an Adult Patient. *PLoS ONE* **2011**, *6*, e25434, doi:10.1371/journal.pone.0025434.
264. Wong, A.H.; Cheng, P.K.; Lai, M.Y.; Leung, P.C.; Wong, K.K.; Lee, W.; Lim, W.W. Virulence Potential of Fusogenic Orthoreoviruses. *Emerg. Infect. Dis.* **2012**, *18*, 944–948, doi:10.3201/eid1806.111688.
265. Smith, I.; Wang, L. Bats and their virome: An important source of emerging viruses capable of infecting humans. *Curr. Opin. Virol.* **2013**, *3*, 84–91, doi:10.1016/j.coviro.2012.11.006.
266. Yamanaka, A.; Iwakiri, A.; Yoshikawa, T.; Sakai, K.; Singh, H.; Himeji, D.; Kikuchi, I.; Ueda, A.; Yamamoto, S.; Miura, M.; et al. Imported Case of Acute Respiratory Tract Infection Associated with a Member of Species Nelson Bay Orthoreovirus. *PLoS ONE* **2014**, *9*, e92777, doi:10.1371/journal.pone.0092777.
267. Duncan, R. Extensive Sequence Divergence and Phylogenetic Relationships between the Fusogenic and Nonfusogenic Orthoreoviruses: A Species Proposal. *Virology* **1999**, *260*, 316–328, doi:10.1006/viro.1999.9832.
268. Duncan, R.; Murphy, F.A.; Mirkovic, R.R. Characterization of a Novel Syncytium-Inducing Baboon Reovirus. *Virology* **1995**, *212*, 752–756, doi:10.1006/viro.1995.1536.
269. Salsman, J.; Top, D.; Barry, C.; Duncan, R. A Virus-Encoded Cell–Cell Fusion Machine Dependent on Surrogate Adhesins. *PLoS Pathog.* **2008**, *4*, e1000016, doi:10.1371/journal.ppat.1000016.
270. Ciechonska, M.; Key, T.; Duncan, R.; Tesfay, M.Z.; Ammayappan, A.; Federspiel, M.J.; Barber, G.N.; Stojdl, D.; Peng, K.-W.; Russell, S.J.; et al. Efficient Reovirus- and Measles Virus-Mediated Pore Expansion during Syncytium Formation Is Dependent on Annexin A1 and Intracellular Calcium. *J. Virol.* **2014**, *88*, 6137–6147, doi:10.1128/jvi.00121-14.

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).